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     BK Polyomavirus (BKPyV) is a widespread human pathogen that establishes a lifelong 
persistent infection in the kidneys and can cause severe disease in immunosuppressed patients. 
BKPyV is a nonenveloped DNA virus whose productive intracellular trafficking pathway 
requires trafficking through the endoplasmic reticulum (ER); however, it is unclear how BKPyV 
exits the ER and undergoes nuclear entry. In this dissertation, I elucidated the role of the ER-
associated degradation (ERAD) pathway and show that BKPyV traffics through the cytosol en 
route to the nucleus. Furthermore, I determined the importance of the nuclear localization signal 
located on the minor capsid proteins VP2 and VP3 during BKPyV intracellular trafficking. These 
studies were performed in renal proximal tubule epithelial (RPTE) cells, a natural host cell, and 
provide a relevant model for BKPyV infection.   
     Using proteasome and ERAD inhibitors, I showed that ERAD is required for productive 
entry. Altered trafficking and accumulation of uncoated viral intermediates was detected by 
fluorescence in situ hybridization and indirect immunofluorescence in the presence of inhibitor.  
Additionally, I detected a change in localization of partially uncoated virus within the ER during 
proteasome inhibition, from a BiP-rich area to a calnexin-rich subregion, indicating BKPyV is 
accumulating in an ER subcompartment. Interestingly, inhibiting ERAD did not prevent entry of 
capsid protein VP1 into the cytosol from the ER. By comparing the cytosolic entry of the related 
polyomavirus SV40, I found that trafficking results varied between different cell types, namely, 
immortalized CV-1 cells versus primary RPTE cells. By measuring viral DNA in the cytosol, 
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however, I found that ERAD inhibition led to a decrease in cytosolic viral DNA, regardless of 
appearance of VP1 monomers, supporting a role for ERAD in ER exit into the cytosol.  
     To elucidate the nuclear entry mechanism, a nuclear localization signal (NLS) in the basic 
region of the C-terminus of both minor capsid proteins was first shown to be important for 
nuclear localization by site directed mutagenesis. The analogous mutation in the genome caused 
attenuation of infectivity based on an entry defect post-ER trafficking. The role of the NLS in the 
individual minor capsid proteins was addressed using pseudovirions containing mutations in one 
or both of the minor capsid proteins. Only mutation of the VP3-NLS led to an attenuated 
phenotype in 293TT cells. Overall these data are the first to show that BKPyV traffics through 









1. POLYOMAVIRUSES  
History and Epidemiology  
BK Polyomavirus (BKPyV), named for the initials of the patient from whom it was isolated, 
was one of two of the first human polyomaviruses discovered. BKPyV and the other human 
virus, JCPyV, were both discovered in 1971 in the urine and brain tissue, respectively, of two 
different immunocompromised patients (1, 2). Before these human polyomaviruses, only four 
other polyomaviruses were known: two from mice (mouse polyoma and K virus), one from 
rabbits (rabbit kidney vacuolating virus), and one originating from monkeys called Simian 
Vacuolating virus 40. SV40 had been discovered in 1960 as a contaminant in cell cultures used 
for the polio vaccine, bringing the possible consequences of the DNA tumor virus infection to 
the consideration of the scientific field (3, 4).  
Since initial studies began on the first few polyomaviruses mentioned above, recent efforts 
toward new virus discovery have uncovered a plethora of new polyomaviruses from various 
species, including nine new human polyomaviruses. While these viruses share the distinct 
genome architecture to distinguish them as polyomaviruses, significant differences exist 
throughout the genome sequences, suggesting the loss or gain of different viral protein features 
(5). This aspect of polyomavirus evolution will be discussed more in Chapter 4. Polyomaviruses 
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have been discovered in urine, stool, blood, skin, lesions, or nasopharyngeal tissue and 
appear to be significant members of the microbiota, with seroprevalence in the population 
ranging from about 50 – 90% (6). While some were found in normal healthy samples, others 
were found associated with a disease state. Association with disease tissue does not 
automatically imply causality, but Merkel Cell polyomavirus (MCPyV) has been firmly linked 
with the rare but aggressive skin cancer Merkel cell carcinoma, making it the first clear 
oncogenic human polyomavirus (7). However, the oncogenicity of MCPyV relies on the rare 
event of viral genome integration into the host cell genome.  
BKPyV has approximately 80-90% seroprevalence in the population. It is thought that 
transmission is likely through a respiratory route in early childhood, since viral DNA has been 
detected in tonsillar tissue and seroprevalence reaches 65-90% by the age of ten. Other potential 
routes of transmission have been proposed, including fecal-oral, urino-oral, transplancental, and 
through blood transfusion. Primary infection is believed to range from asymptomatic to a mild 
respiratory ailment (8). After initial infection, BKPyV establishes a persistent infection in the 
kidneys and urinary tract with sporadic replication that can be detected in the urine. It is 
unknown how the virus comes to persist in kidney cells and whether the viral genome undergoes 
true “latency” or simply replicates at a low level that is kept under control by an intact immune 
system. The latter theory is favored as periodic shedding of high virus titers can be detected in 
healthy persons.  
There are two different forms of BKPyV that can be isolated from infected persons, and these 
forms include archetype virus and rearranged variants. The difference lies in their genomic 
structure. The circular BKPyV genome is made up of three distinct regions, including the early 




Figure 1.1. Representation of the Polyomavirus genomic structure.  The non-coding 
control region (NCCR), containing the origin of replication and regulatory 
sequences, is located at the bottom of the diagram. The early region is located on the 
left and late region on the right. Regulatory proteins large T antigen (TAg), small t-
antigen (tAg), and recently identified truncated TAg (truncTAg) are expressed form 
the early region, with agnoprotein (agno) and structural proteins VP1, VP2, and VP3 
expressed from the late region. 
4 
 
rearranged variants have sequence variations distinctly found in the NCCR and are most 
commonly isolated from the blood serum of diseased patients only. Archetype virus is the most 
commonly isolated form of BKPyV and has a distinct sequence structure to the NCCR. 
Archetype is found in healthy as well as diseased patients, suggesting that archetype virus is the 
transmitted form of BKPyV (8).  
 
BKPyV Structure  
BKPyV is a non-enveloped virus, without a surrounding lipid bilayer, and consists of only a 
protein capsid and DNA genome. The particle is approximately 40 nm in size as determined by 
electron microscopy. The BKPyV particle consists mainly of three molecules that serve as the 
building blocks for the structure of the viral capsid: the major structural protein VP1 and less 
abundant minor capsid proteins VP2 and VP3 (see Figure 1.2). The capsid surrounds the 5 kb 
double stranded circular DNA genome that is complexed with histones in the form of a miniature 
chromosome. The outer shell of the virus capsid consists solely of VP1 proteins arranged in 
pentamers in a T=7 icosahedral lattice, and these pentamers are stabilized by intra- and inter-
pentameric disulfide bonds and calcium cations. Sixty of the 72 pentamers, or capsomeres, are 
coordinated  with six adjacent pentamers, and the other twelve of the 72 pentamers are located 
on the icosahedral vertices of the capsid,  coordinated with five surrounding pentamers (9). The 
importance of these different arrangements within the VP1 shell is likely seen during the capsid 
disassembly process, as differing inter-pentameric interactions require stepwise uncoating, and 
this gradual disassembly is used during intracellular trafficking towards the nucleus (10).  
On the internal face of each VP1 pentamer, not surface-exposed on the intact viral particle, is 
one molecule of either VP2 or VP3 (11). The minor capsid proteins are expressed from the same 
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late mRNA transcript and share a C-terminal amino acid sequence, but VP2 has a unique set of 
N-terminal amino acids that include a putative myristoylation site. Both SV40 and mouse 
polyomavirus (MPyV) have been shown to contain myristoylated VP2 (12). The stoichiometric 
ratio of VP2 to VP3 is not equal, and the functional significance of that ratio is unknown; 
however, it is believed that each of these minor capsid proteins plays a unique and vital role in 
cellular entry and assembly based what has been seen with SV40 (13, 14). Together, the features 
of this simple particle somehow play a role in both stabilizing the virus outside of the cell and 
enabling the virus to traverse the obstacle course of the cellular interior and eventually enter the 
nucleus, the site of replication.   
 
2. BK POLYOMAVIRUS –ASSOCIATED DISEASE  
As previously mentioned, a normal immune system will keep BKPyV replication at a 
minimum and prevent the onset of a diseased state. However, under conditions of immuno- 
deficiency or suppression, BKPyV reactivation in the kidney or urinary tract can go unrestricted 
and result in lytic infection and destruction of tissue. This occurs most often in bone marrow 
transplant patients and kidney transplant patients, but can also occur in other 
immunocompromised individuals including other solid organ transplant recipients, persons with 
acquired immune deficiency syndrome (AIDS), or sufferers of autoimmune diseases such as 
systemic lupus erythematosus (15).  
One of the more common diseases caused by BKPyV infection is hemorrhagic cystitis (HC) , 
affecting 10-25% of bone marrow transplant patients sometime after 2 weeks post-
transplantation. BKPyV-associated HC is verified based on the presence of decoy cells in the 




Figure 1.2. Representation of the Polyomavirus capsid structure, based on SV40. 
The outer shell of the capsid consists of VP1 pentamers, creating a structure with 
T=7d icosahedral symmetry (right). Minor capsid proteins VP2 and VP3 reside 
underneath the pentamers, hidden from surface-exposure, along with the circular 5 
kb histone-complexed genome (left). Figure taken from SIB Swiss Institute of 
Bioinformatics.   
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BKPyV viruria (or viremia). The symptoms include painful, bloody urination and the only 
treatment is palliative, with pain-relief, bladder irrigation, and transfusions in severe cases (15).  
Another BKPyV associated disease is polyomavirus-associated nephropathy (PVAN), which 
can arise in kidney transplant patients approximately 10-13 months after renal transplant. PVAN 
effects up to 10% of kidney transplant patients and can cause graft loss in 90% of those afflicted. 
Because it occurs most often in the allograft, it is believed that it is typically brought about from 
a combination of immunosuppression and tissue injury that lead to uncontrolled replication of 
BKPyV, rather than immunosuppression alone (16). Symptoms of PVAN include increased 
serum creatinine levels, presence of viruria and decoy cells in the urine, and viremia. Biopsy of 
the infected kidney is the most straightforward detection of PVAN, in which intranuclear viral 
inclusion bodies in epithelial cells and virally induced tubular epithelial cell injury and lysis 
would be evident. Treatment for PVAN is palliative, and the most successful management 
includes reduction of the immunosuppressive regimen to allow for the host immune system to 
regain control of the infection (17). 
Besides kidney and bladder epithelial cells, viral DNA has been found in other areas of the 
body and tissue types, including urogenital and brain tissue and peripheral blood mononuclear 
cells and spleen (16). These other sites of viral detection suggest that there may be an immune 
cell component in the dissemination of BKPyV. The significance of the presence of virus in 
these other tissues in terms of latency or disease, however, is unclear. On the other hand, light 
and electron microscopic evidence from biopsies of PVAN patients shows that BKPyV clearly 
undergoes lytic infection in renal proximal tubule epithelial (RPTE) cells in vivo (18, 19). 
Because of this, our lab has established an in vitro cell culture model using primary RPTE cells 




3. VIRAL LIFECYCLE  
Receptor Binding 
In order to establish a persistent or lytic infection and cause disease, BKPyV must be 
internalized into a host cell type that is permissive to infection. This may include a number of 
different cell types and different tissues throughout the body. The main site of reactivation and 
replication, however, is within the kidneys and urinary tract, and thus the cell types commonly 
used for studies of cellular entry are cell lines or primary cells of renal epithelial origin. For a 
general overview of the lifecycle, see Figure 1.3. 
Successful infection of a cell requires attachment to the cell surface and functional 
interaction with the surface receptor that will lead to internalization of the virus and targeting to a 
productive pathway. The presence or absence of a functional receptor often plays a determining 
role in the tropism of viruses. Initial studies to identify the nature of the BKPyV receptor clearly 
pointed to gangliosides as an important factor. Hemagglutination was observed in the very first 
characterization assays for BKPyV, and this could be inhibited by preincubating with 
gangliosides (21). The first studies were done with Vero cells, a monkey-derived kidney cell 
line, and were later repeated with the relevant cell culture model of human renal proximal tubule 
epithelial (RPTE) cells (22). Pretreatment of RPTE cells with neuraminidase, but not proteinase 
K, abolished binding and infection. Studies with RPTE cells verified the presence of a sialic acid 
component, and went on to identify the specific gangliosides GD1b and GT1b as binding 
partners in a sucrose flotation assay. Infection of non-susceptible cells is made possible by the 
exogenous addition of each of these gangliosides (23). Likewise, infection of RPTE cells with 




Figure 1.3. General overview of the BKPyV lifecycle from receptor binding to 
assembly. For details, see text. Figure created by Mengxi Jiang. 
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(22). A commonality between the GD1b and GT1b gangliosides is an α2-8-linked disialic acid 
motif, but whether this presents a potential site of interaction between receptor and capsid 
remains to be determined, and this will require the 3-dimensional structure of the capsid with the 
receptor.  
 
Internalization and endocytosis 
     After binding its receptor, BKPyV must enter the cell and successfully traffic through the 
cytoplasm toward the nucleus, where the uncoated viral genome can utilize the cellular 
machinery for transcription and its genome replication. Early studies to determine the cellular 
entry pathway taken by BKPyV were based on transmission electron microscopy (TEM) of 
infected cells at different times post infection, and these images show virions taken into the cell 
by small, tight-fitting, non-coated vesicles, trafficking to smooth tubular structures contiguous 
with rough endoplasmic reticulum (ER), and entering the nucleus as relatively intact particles. 
Since single virus particles could be seen in the nucleus at a relatively early time before progeny 
would likely have been produced, and because they appeared smaller than virions at the plasma 
membrane, these were believed to be partially-disassembled incoming virions  (24) (25).  
     Besides the information from TEM of BKPyV-infected cells, our understanding of the entry 
pathway of BKPyV was also initially based on inferences made from findings with SV40, and to 
some extent with the more distantly related mouse polyomavirus (MPyV), due to their earlier 
discovery and established cell culture models. However, it has recently become clear that 
interesting and significant differences exist between the biology of BKPyV and other 
polyomaviruses, including the role of different ganglioside receptors, as mentioned above. Thus, 
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more detailed analyses of the specific interaction between virus and host cell will be necessary to 
gain a deeper understanding of how BKPyV establishes an infection. 
     Following receptor binding, internalization of BKPyV is dependent on a caveolae-mediated 
endocytic pathway (26). This differs from what was found with JCPyV, which relies on clathrin-
dependent receptor-mediated endocytosis (27). Caveolae are a type of specialized microdomain 
invagination in the plasma membrane that are enriched in cholesterol, and formation is 
dependent on caveolin proteins such as caveolin-1 (28). Caveolae-mediated entry by BKPyV 
was discovered from data showing that expression of a dominant-negative caveolin-1 construct 
decreased infection, and depletion of membrane cholesterol with methyl-B-cyclodextrin had an 
inhibitory effect, since caveolae are disrupted with cholesterol depletion (29, 30). A knockdown 
of caveolin-1 also showed its role in BKPyV infection in RPTE cells (29). Additionally, 
expression of an Eps15 dominant-negative construct, which prevents clathrin-dependent 
endocytosis by targeting a necessary component in assembly of clathrin pits (31), did not prevent 
infection in Vero cells (32). Verification of the pathway was also confirmed when co-localization 
of fluorescently labeled virions with cholera toxin B, which serves as a marker of caveolae 
endocytosis, was observed during synchronized entry (29, 30) (32). Additionally, BKPyV 
allograft nephropathy analyzed by EM shows virions close to the plasma membrane in 60-70 nm 
smooth vesicles whose description is consistent with that of caveolae, confirming this vesicular 
route in a natural infection setting [51].  
     Studies show internalization to be relatively slow and nonsynchronized (32, 33). The details 
of the endocytic pathway taken by BKPyV has not yet been defined. However, it is known that 
SV40 depends on the classical endocytic route through early and late endosomes towards 
endolysosomes and relies on acidification and maturation of endosomes for entry (34). It is likely 
12 
 
the route taken by BKPyV as well, and it has been shown that BKPyV requires an acidification 
step very early during entry in RPTE cells (33). Although JCPyV enters via a clathrin-mediated 
route, it is taken into early endosomes like SV40, and the virus is then directed to an unidentified 
compartment by a caveolin-1 dependent step (35). These studies together show that cross-talk 
between endocytic pathways allows for differences in the initial entry steps of receptor-mediated 
binding and endocytosis between each virus, while later intracellular trafficking steps are likely 
more parallel as the virus reaches the ER (36). 
     Approaches using various pharmacological treatments of infected cells have established the 
need for microtubules during trafficking, but apparently not actin (37). Treatment with the drug 
nocodazole, which destabilizes microtubules, was found to inhibit infection at an early time 
point, as well as tests with the microtubule destabilizing agent colcemid in RPTE cells. (33, 38)  
Paclitaxel, a microtubule stabilizer, inhibited infection in RPTE cells as well, which was 
surprisingly different from what was seen in Vero cells, and supports the relevancy of an in vitro 
primary host cell model. Another study addressed the role of dynein, the microtubule motor 
protein, using the drug EHNA (erythro-9-[3-(2-hydroxynonyl)] adenine) that inhibits the ATPase 
of the dynein complex, and showed independence of BKPyV infection from dynein in RPTE 
cells (39). Interestingly, however, this study supports the idea that the Golgi apparatus is 
bypassed during the retrograde trafficking route of BKPyV, since EHNA disrupts the 
morphology of the Golgi apparatus but did not affect BKPyV infection.  
 
ER trafficking and Virus Uncoating 
     After following an endocytic trafficking route, the virus reaches the ER. Trafficking through 
the ER seems to be a necessary step for all polyomaviruses. This aspect of polyomavirus entry is 
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unique among DNA viruses, which raises the question of what benefit the ER provides during 
entry. One main advantage within the compartment of the ER is that it contains chaperones, 
disulfide isomerases, and reductases of which the virus can make use to facilitate the capsid 
uncoating and disassembly process. Evidence from SV40 and MPyV points toward involvement 
of the ER-localized protein disulfide isomerase (PDI) family in providing the reduction and 
isomerization of the VP1 capsid proteins that provides an initial and vital step in the uncoating 
process (33, 40, 41). The interactions and subsequent conformational changes that occur within 
the ER compartment likely also provide the means for the virion to continue on its pathway into 
the nucleus.  
     So far, a number of ER resident host factors that are involved in SV40 and MPyV infection 
have been identified, providing a theoretical framework for the interactions of BKPyV during ER 
trafficking and uncoating. It was found for MPyV that the PDI family member ERp29 causes a 
conformational change in VP1, shown by exposure of a trypsin-sensitive site, and that this results 
in the viral particle being able to interact with a lipid bilayer (42). Other PDI family members 
PDI, ERp57, and ERp72 were later shown to work in concert for reduction and isomerization of 
specific disulfide bonds within the MPyV capsid, and these changes are necessary for uncoating 
[68]. Schelhaas et al. had shown that the same scenario and host factors are important for SV40. 
MPyV was also found to require the ER transmembrane protein Derlin-2 for infection (41, 43, 
44).  
 
ER-associated degradation  
     Involvement of members of the Derlin-family proteins provides an interesting link between 
infection and the process of ER-associated degradation (ERAD), a cellular quality control 
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mechanism for sending misfolded proteins out of the ER into the cytosol where they are 
degraded by the proteasome (45). Derlins have been found to be important for infection with 
both MPyV and SV40, as well as BKPyV. Derlin-1 was found to be essential for BKPyV 
infection by transiently expressing a dominant negative construct during infection, and was 
implicated in SV40 infection through siRNA-mediated silencing (33). A role for the proteasome 
has also been shown during BKPyV infection, as well as for SV40, and this suggests the 
importance of the ubiquitin-proteasome system during entry, which is part of ERAD (40, 46).  
     The mechanism and regulation of the ERAD pathway is an active area of investigation in the 
field of cell biology. The basic function of the ERAD pathway is to recognize newly translated 
secretory proteins in the ER that do not undergo proper folding, or it can be used in a regulatory 
capacity (47). Common features of the pathway shared by all substrates include recognition of 
the substrate, shuttling of the substrate to the retrotranslocation machinery at the ER membrane, 
retrotranslocation of the substrate across the membrane and into the cytosol, ubiquitination, and 
degradation by the proteasome. The degradation of ER proteins was initially believed to occur by 
an unknown protease within the ER lumen, but later it was discovered that the proteasome, 
located in the cytosol, was responsible for the degradation of aberrant proteins. This finding was 
intriguing since it raised an interesting topology question of how the ER-resident proteins made 
it across the membrane to the cytosol and the proteasome. To date, it is still uncertain if there is a 
specific protein that serves as a retrotranslocation pore, or if a channel is formed by an assembly 
of transmembrane proteins.  Derlin-1 has been proposed to serve as the channel (48), as has an 
E3 ligase Hrd1 (49), and the translocation channel Sec61 (50). It has also been proposed that 
different substrates may use different channels or mechanisms of retrotranslocation. Besides the 
putative channel components, many lectins and chaperones are involved in the process of 
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handling and targeting different ERAD substrates. The mechanism and components of the 
endogenous ERAD pathway are still being described, and many questions remain to be 
answered. 
     A few recent studies have identified components of the ERAD machinery to be involved 
during SV40 trafficking. These studies were able to demonstrate directly that viral trafficking 
from the ER to the cytosol was inhibited upon disrupting the ER chaperones BiP and its 
interacting partner DNAJB11, as well as the transmembrane shuttle BAP31 (51, 52). The minor 
capsid proteins VP2 and VP3 were also shown to be required for this retrotranslocation across 
the ER membrane by using a pseudovirus consisting of a VP1-only capsid, which was unable to 
enter the cytosol (51). It has yet to be elucidated what mechanisms are used for BKPyV 
trafficking from the ER to the nucleus, but evidence suggests that use of the ERAD-associated 
factors to enter the cytosol is conserved among polyomaviruses. 
 
Nuclear Entry 
     The pathway used by BKPyV to get into the nucleus is currently unknown. Evidence for 
SV40 suggests that the virus may use the canonical route through the nuclear pore complex. 
Since previous work with SV40 implies a model where the virus traffics through the cytosol, it is 
reasonable to hypothesize that the virus would then use the canonical nuclear import pathway 
through the nuclear pore for nuclear entry. The full sized virion at ~45 nm (53) would be too big 
to fit through the nuclear pore, but partial disassembly could allow it to pass through if smaller 
than 39 nm (54). A nuclear localization signal is located on each of the capsid proteins but none 
are exposed in the intact particle, so partial disassembly that occurs in the ER and/or cytosol 
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would be a likely prerequisite for the canonical use of this pathway, especially since evidence 
from SV40 suggests that the minor capsid proteins are required for nuclear entry (14).  
 
Canonical Nuclear Import Pathway 
     Since viruses often co-opt existing cellular pathways, a model where polyomaviruses use the 
canonical nuclear import pathway is favored, since this would follow cytosolic trafficking. The 
nuclear pore complex is an enormous assembly of proteins that spans both the inner and outer 
nuclear membranes. The pore itself consists of 30 different proteins in multiple copies, making 
up a macromolecular complex of 500-1000 total subunits (55). The pore size seems to be 
flexible, with the largest observed opening at about 39 nm (54). Small molecules and ions can 
diffuse through passively, but larger molecules use a string of basic amino acids that make up a 
“signal sequence” recognized by specific shuttling proteins that bring it through the pore 
complex. It is still unclear exactly how the protein complexes are actively taken through the 
pore, but one favored model involves an affinity gradient, where the favorability of the 
interactions between substrate and pore proteins continually increases as it goes through the 
channel (53, 56). 
     The classic import pathway first involves recognition of the signal sequence, or NLS, by the 
adapter protein importin alpha. Once importin alpha recognizes and binds to an NLS, another 
shuttle protein, importin beta, binds importin alpha and takes the complex through the nuclear 
pore. Once inside the nucleus, importin beta interacts with RanGTP to release the cargo (53). 
Nakanishi et al.(57-59) have provided a notable amount of evidence for the use of the canonical 
nuclear import pathway by SV40 for nuclear entry through the nuclear pore. SV40 DNA can be 
co-immunoprecipitated with importin alpha and beta, and the importins can be co-
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immunoprecipitated with VP3, and only during time points early in infection (58, 59). They also 
showed that the nuclear localization signal (NLS) shared by the minor capsid proteins VP2/VP3 
is vital for nuclear entry, implying that the signal becomes exposed during infection and is used 
for nuclear import through the pore (58, 59). Interestingly, it has also been shown that the 
nuclear localization signal on VP2 and VP3 is unnecessary for nuclear import in the presence of 
functional VP1, since VP1 seems to bring the VP2 and VP3 into the nucleus during production 
of progeny virions. 
     Besides nuclear import, another possible nuclear entry mechanism is for the virus particle to 
traverse the inner nuclear membrane directly from the ER, and there are some pieces of evidence 
suggesting that this pathway may exist. One recent paper on SV40 shows that there are small 
changes in the nuclear envelope and transient perturbations in the nuclear lamina during early 
times in infection, and these are associated with cleavage of lamin A/C (60). Another 
ultrastructure-based investigation of BKPyV-infected kidney tissue showed some malformations 
in the nuclear envelope adjacent to accumulations of virions, and no virions were found near the 
nuclear pore (18). Since these ultrastructural observations were made in diseased tissue, 
however, it is difficult to determine the stage of the lifecycle occurring in each cell, and whether 
the observations are representative of a typical infectious route. To date, there is no evidence 
against either of these possible pathways, and there is no indication that they are mutually 
exclusive nuclear entry models. 
 
Regulatory proteins 
     Once the uncoated viral genome is inside the nucleus, BKPyV takes advantage of nuclear 
factors to allow the temporal expression of its viral genes. The three regulatory proteins, Large 
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Tumor (T) Antigen (TAg), small T antigen (tAg), and truncated T antigen (truncTAg) are 
expressed first, followed by initiation of replication, and then late gene expression [10]. The 
early and late promoters are located in the NCCR, in opposite orientations like their coding 
regions, on the 5 kb genome. The NCCR additionally contains the origin of replication, and 
multiple binding sites for regulatory factors of cellular origin have been identified within this 
regulatory region (61). The early promoter drives expression of a primary transcript, which is 
alternatively spliced to allow for expression of the three early proteins. Once the regulatory 
function of TAg is active, DNA replication begins, followed by expression of the late proteins 
VP1, VP2, VP3, and agnoprotein (10).  
     TAg is an impressively multifunctional regulatory protein, responsible for directly interacting 
with the viral genome to initiate DNA unwinding, as well as exhibiting functions that allow 
expression of the cellular DNA synthetic machinery that can support viral replication. These 
functions include binding to the retinoblastoma (Rb) protein and its family members (p107 and 
p130) to alleviate E2F-mediated transcriptional repression, as well as binding to p53 and 
inhibiting its downstream tumor suppressor targets to block apoptosis and allow maximal 
production of viral progeny (62, 63). The tAg shares an N-terminus with TAg, and thus shares 
the interactions and functions mediated by the domains located in the N-terminus, such as the J-
domain (64). One unique function of tAg is its inactivation of protein phosphatase 2A via 
formation of a complex with the catalytic and regulatory subunits. This leads to increased cyclins 
D1 and A, and downregulated p27, which are factors in the control of cell cycle progression (65-
67). Any unique functions of the truncTAg protein have yet to be elucidated; however, it shares 
133 N-terminal amino acids with TAg followed by three unique amino acids, and thus likely 
serves some redundant roles for  TAg functions (68).  
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     The cell cycle-altering functions of the regulatory proteins confer oncogenic properties to 
BKPyV; however, no convincing evidence of oncogenic transformation has been found in 
relation to BKPyV infection of human tissue. Injection of BKPyV into rodents does lead to 
formation of multiple tumors, prompting the question of what host factor interactions lead to 
specific outcomes during infection (69). The viral genome remains episomal in human cells after 
infection, while in rodent cell lines it undergoes integration into the cellular DNA (61). 
Identification of differences in the molecular mechanisms at work in the nuclei of each species 
may provide insights into the basis for maintenance, latency, and lytic replication. 
 
Replication 
     After synthesis of the regulatory proteins and establishment of the DNA synthesis-active 
cellular environment, replication of the viral genome occurs. Replication begins at the origin of 
replication that sits within the NCCR. TAg binds to the viral origin and assembles into a double 
hexamer, which leads to its hydrolysis of ATP, initial unwinding of the viral chromatin through 
its helicase activity, and recruitment of the cellular DNA polymerase /primase complex (69). 
Synthesis occurs in both directions from the replication origin until the replication forks meet on 
the opposite side of the genome. Besides TAg, the minimal molecular requirements for the DNA 
replication of SV40 include RPA, DNA polymerase /primase, topoisomerase I, RFC, DNA 
polymerase delta, and PCNA; this provides a likely scenario for the minimal requirements of  
BKPyV as well (70).  
     Replication of archetype BKPyV has previously been a problem to study in cell culture 
models. Recently, however, Broekema and Imperiale showed propagation of archetype BKPyV 
in 293TT cells, a human embryonic kidney cell line that overexpresses SV40 TAg (71). The 
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abundance of this exogenous regulatory factor was able to compensate for the usually 
undetectable level of BKPyV TAg expression from the archetype virus. Rearranged NCCR 
BKPyV variants grow readily, and thus far these variants have been used as the experimental 
laboratory system. The archetype BKPyV NCCR is characterized by a linear O-P-Q-R-S block 
structure, where O is named for the origin of replication and the blocks that follow are named 
arbitrarily. The early and late region promoters are located in the P-Q-R-S region. Rearranged 
variants are characterized by deletions and duplications of these blocks of sequence within the 
NCCR.  It has yet to be determined which differences between the archetype and rearranged 
NCCR variants affect replication ability, since archetype is usually the form shed from a host.  It 
is possible that the cell type permissive for archetype has not yet been discovered. Some 
investigations have addressed the levels of replication and progeny production in different 
NCCR variants, but little information nor a pattern has emerged as to which of the arbitrary 
blocks, duplications, or deletions affect the ability of BKPyV to replicate in cell culture (61, 72, 
73). 
     Robust late mRNA expression for production of the structural proteins occurs after the 
regulatory proteins have been produced and begun initiation of DNA replication (61). The capsid 
proteins VP1, VP2, and VP3 are produced in the cytoplasm and imported into the nucleus, where 
virion assembly occurs. Progeny virus particles form when capsomeres assemble around newly 
synthesized genomes. This assembly can also incorporate plasmids of non-viral origin or small 
cellular DNAs. Assembly can also result in empty particles that contain no nucleic acid (74). 
New progeny virions accumulate within the nucleus and can be seen clearly by TEM, often in a 
crystalline lattice arrangement, as a sizeable nuclear inclusion. The means of viral egress for 
polyomavirus is not clear; however, it had been believed that profuse accumulation of viral 
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progeny particles within the nucleus cause engorgement and strain on the nuclear envelope and 
eventual lysis of the cell (24). Recent studies on SV40 have identified a fourth structural protein 
protein expressed late in infection called VP4 that can form pores in cellular membranes, 
suggesting a mechanism for egress of SV40 progeny (75, 76). A homologous VP4 protein has 
not been identified for BKPyV, and although VP2 and VP3 may have membrane-lytic properties 
that could contribute to cell lysis late in infection, this has not been observed. 
 
4. SUMMARY OF CHAPTERS 
A significant question in the field of nonenveloped virus entry is the question of how protein 
capsids cross the limiting membrane that allows them eventual access to the nuclear machinery. 
By understanding more details of how BKPyV crosses the ER membrane and enters the nucleus, 
particularly in a natural host cell type, I hope that a greater understanding of nonenveloped virus 
trafficking in general can be gained.  
The objectives of this thesis work were to further elucidate the intracellular trafficking 
pathway of BKPyV in RPTE cells. In Chapter 2, I show that the ERAD pathway is involved 
during infection, and blocking the pathway leads to accumulation of virus in the ER in a quality 
control subcompartment specific for ERAD substrates. I also showed that BKPyV indeed traffics 
through the cytosol and that proteasome inhibition leads to a decrease in viral DNA in the 
cytosol. Chapter 3 shows that a nuclear localization signal is located on the C-terminus of VP2 
and VP3 and that this signal is important for optimal entry of the virus during infection, although 
alternative nuclear entry mechanisms appear to exist as well. In Chapter 4, I discuss the 
implications of these findings and future investigations that can be done to follow up on our 
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Role of Cell Type-Specific ER-associated Degradation in Polyomavirus Trafficking 
 
 
BK Polyomavirus (BKPyV) is a widespread human pathogen that establishes a lifelong 
persistent infection and can cause severe disease in immunosuppressed patients. BKPyV is a 
nonenveloped DNA virus that must traffic through the endoplasmic reticulum (ER) for 
productive infection to occur; however, it is unknown how BKPyV exits the ER before nuclear 
entry. In this study, we elucidate the role of the ER-associated degradation (ERAD) pathway 
during BKPyV intracellular trafficking in renal proximal tubule epithelial (RPTE) cells, a natural 
host cell.  Using proteasome and ERAD inhibitors, we show that ERAD is required for 
productive entry. Altered trafficking and accumulation of uncoated viral intermediates was 
detected by fluorescence in situ hybridization and indirect immunofluorescence in the presence 
of inhibitor.  Additionally, we detected a change in localization of partially uncoated virus within 
the ER during proteasome inhibition, from a BiP-rich area to a calnexin-rich subregion, 
indicating BKPyV is accumulating in an ER subcompartment. Furthermore, inhibiting ERAD 
did not prevent entry of capsid protein VP1 into the cytosol from the ER. By comparing the 
cytosolic entry of the related polyomavirus SV40, we found that dependence on the ERAD 
pathway for cytosolic entry varied between the polyomaviruses and between different cell types, 




     BK Polyomavirus (BKPyV) is a human pathogen that is ubiquitous throughout the 
population. Studies show that up to 90% of adults are seropositive for BKPyV, which is believed 
to infect individuals during early childhood and establish a persistent subclinical infection for the 
lifetime of the host (1). While BKPyV does not usually cause disease in healthy individuals, it 
can lead to severe disease in immunocompromised patients, particularly in bone marrow and 
kidney transplant patients. Under conditions of immunosuppression, reactivation of BKPyV in 
the bladder or kidney causes hemorrhagic cystitis or polyomavirus-associated nephropathy 
(PVAN), respectively. There are currently no effective antivirals against BKPyV, and the current 
treatment protocol is palliative, or, in renal transplant patients, reduction of immunosuppressive 
therapy, leaving the patient vulnerable to graft rejection. Graft loss occurs in up to 50% of cases 
of PVAN (2), either due to the virus or rejection. Before useful antiviral drugs can be developed, 
a deeper understanding of the BKPyV life cycle is necessary, including the details of 
intracellular entry. These early interactions between BKPyV and the host cell have yet to be fully 
elucidated. 
     In the interest of studying BKPyV in a relevant biological setting, our lab previously 
established a cell culture model of BKPyV infection using primary renal proximal tubule 
epithelial (RPTE) cells (3). This is based on the observation of histologic sections and 
transmission electron micrographs of PVAN patient biopsies, indicating lytic infection by 
BKPyV in RPTE cells (4-6). We have shown that the intracellular trafficking pathway of 
BKPyV in RPTE cells begins with binding to the ganglioside receptors GT1b and GD1b, 
followed by internalization and a pH-dependent step within the first two hours after adsorption. 
The virus subsequently relies on microtubules (7-9) and traffics through the endocytic pathway 
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to the ER, where it arrives approximately 8 hours post infection (hpi) (9). Sometime after ER 
trafficking but before 24 hpi the virus enters the nucleus, where transcription of early regulatory 
genes occurs, followed by DNA replication and late gene expression. It is unknown, however, 
how BKPyV gets from the ER to the nucleus. Two possible routes have been proposed: the virus 
can cross the inner nuclear membrane directly from the ER lumen, or the virus can cross the ER 
membrane into the cytosol from where it can subsequently enter the nucleus, likely via the 
nuclear pore complex.  
     In order for the BKPyV genome to undergo replication and transcription in the nucleus, it 
must be uncoated and released from the viral capsid. The BKPyV capsid structure consists of 
three proteins, VP1, VP2 and VP3. The major capsid protein, VP1, oligomerizes into pentamers 
during virion production and makes up the outer shell of the particle, with 72 pentamers 
stabilized by inter- and intra-disulfide bonds (10). It is believed that these disulfide bonds 
become reduced and/or isomerized by host disulfide reductases and isomerases when the virus 
infects a naïve cell and traffics through the ER (9, 11). One molecule of either minor capsid 
protein, VP2 or VP3, is associated with each pentamer, and is concealed by VP1 from antibody 
detection until disassembly begins in the ER (12, 13). 
     Evidence from previous studies has implicated a role for components of the ER-associated 
degradation (ERAD) pathway during infection of polyomaviruses (14-17). ER quality control 
mechanisms of the cell include the ERAD pathway as a means by which secretory proteins in the 
ER that cannot attain their proper conformation are sent into the cytosol and degraded by the 
proteasome (18). The feature of ERAD that makes it an enticing host pathway for a non-
enveloped virus to co-opt is that it provides a mechanism for ER-localized proteins – in this case 
the viral particle – to be sent across the ER membrane into the cytosol. ERAD depends on an 
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intricate collection of chaperones and transmembrane proteins that recognize a misfolded 
protein, target and shuttle the protein to a retrotranslocation complex, translocate the substrate 
across the ER membrane into the cytosol where it is ubiquitinated, and send it to the proteasome 
for degradation (18). One set of ERAD translocation complex proteins, the Derlin family, has 
been found to be necessary for mouse polyomavirus, SV40, and BKPyV, through experiments 
with siRNA knockdowns or dominant-negative constructs (9, 14, 17). Proteasome function has 
also been shown to be necessary for both SV40 and BKPyV infection (9, 14), and treatment with 
the proteasome inhibitor lactacystin resulted in an increase in disassembly products of the 
BKPyV capsid (9, 14), suggesting that blocking proteasome function may alter the disassembly 
and entry pathway of BKPyV. 
     It was the goal of this study to further investigate the entry route of BKPyV during and after 
ER trafficking, focusing on the role of the ERAD pathway and the proteasome. This is the first 
study to examine polyomavirus ER-to-cytosol trafficking in the context of a natural host cell. We 
show that the proteasome and ERAD system do play a role in the trafficking of BKPyV, as 
specific inhibitors block an early step during infection. We also show that proteasome inhibition 
causes a change in the ER localization of BKPyV and an accumulation of detectable VP2/3 
protein, indicating disassembled particles in the ER. Additionally we provide evidence that 
BKPyV enters the cytosol. Interestingly, however, we show that proteasome and ERAD 
inhibitors do not prevent BKPyV VP1 protein from entering the cytosol. Moreover, our data 
suggest that differences exist in the trafficking of polyomaviruses in different cell types, as seen 
with both BKPyV and SV40 in RPTE cells as compared to CV-1 cells. Altogether this report 
provides new evidence that the ERAD pathway is involved during BKPyV entry, and that there 





Productive infection requires the proteasome and ERAD pathway. 
     Because previous studies indicated that the proteasome may play a role during entry of 
BKPyV (9, 14), we became interested in further clarifying the function of the proteasome and 
whether the ERAD pathway is involved during infection. To examine whether the proteasome 
was involved in an early step during infection coincident with transit through the ER, a time 
course of drug treatment was performed to determine when infection would no longer be 
sensitive to proteasome inhibition. We used epoxomicin, which is a potent inhibitor of the 
chymotrypsin-like activity of the proteasome and also blocks the trypsin-like and peptidyl-
glutamyl peptide hydrolyzing activities (19). RPTE cells were subjected to synchronized 
infection with BKPyV, and samples were treated with epoxomicin at different time points post 
adsorption, beginning with 0 h. Whole cell lysates were harvested at 24 hpi, resolved by SDS-
PAGE, and immunoblotted for the early protein, TAg, as a readout for genome delivery to the 
nucleus. Compared to untreated cells, samples with epoxomicin added at time points until 18 hpi 
were inhibited for infection by BKPyV (Figure 2.1, top). These data indicated that BKPyV no 
longer required proteasome function after approximately 18 hpi. These kinetics fit within the 
range of time between ER trafficking and nuclear entry; BKPyV traffics through the ER between 
8 hpi and 16 hpi (9), and early gene expression can be detected beginning at about 24 hpi (3).  
     Since the proteasome can function independently from the ERAD system, we decided to 
address the role of the ERAD pathway during early infection with the ERAD inhibitor, 




Figure 2.1: Timecourse of proteasome and ERAD pathway involvement during infection. 
RPTE cells were infected at 5 IU/cell at 4° C for 1 hr, moved to 37°C and treated at the 
indicated timepoints with either 10 µM epoxomicin (Epox) or 10 µM Eeyarestatin I (EerI). M 
= mock infected, UT = untreated. Whole cell lysates were harvested at 24 hpi, resolved by 
reducing SDS-PAGE, and probed for TAg and GAPDH. Similar results were obtained for at 
least 3 independent experiments.  
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 proteasome as a cytosolic component of the ERAD pathway and is thought to provide the 
driving energy for extraction of ERAD substrates from the ER (21). Interestingly, similar 
inhibition kinetics were seen with Eeyarestatin I as with epoxomicin, a block in TAg expression 
until 18 hpi (Figure 2.1, bottom), which supports the possibility that the proteasome may be 
acting as part of the ERAD pathway to allow BKPyV to exit from the ER. Together these data 
support a role for the proteasome and ERAD during entry of BKPyV, at a step between ER 
trafficking and nuclear entry. 
 
Trafficking of BKPyV is altered by proteasome inhibition.  
     To corroborate results from the drug treatment timecourse, we employed an imaging approach 
to assess the effects of ERAD inhibition on BKPyV trafficking. RPTE cells were infected with 
BKPyV and then treated with epoxomicin or the vehicle DMSO at 6 hpi. Cell viability was not 
affected under these conditions. BKPyV DNA was detected by FISH with a fluorescently labeled 
probe that recognizes the viral genome. At 24 hpi, FISH signals appeared as puncta throughout 
the cell, with some signal adjacent to the nucleus. In the presence of epoxomicin, there was a 
change in the pattern of FISH signals: we saw a slight but reproducible increase in the average 
area of the puncta, representing an accumulation of the virus, in a juxtanuclear position (Figure 
2.2A).  
     FISH staining labels all viral genomes within the cell, regardless of whether they are 
following a productive or non-productive pathway. Because of this ambiguity, we became 
interested in using a viral marker that more likely represents virus that is following a productive 
infectious pathway. As polyomavirus travels through the ER, the capsid begins to disassemble 







Figure 2.2: BKPyV trafficking is altered when ERAD is inhibited. RPTE cells were infected at 5 
IU/cell at 4°C for 1 hr then moved to 37°C. Cells were treated with 10 µM epoxomicin or DMSO at 
6 hpi and fixed at 24 hpi. (A) BKPyV was stained by FISH against the viral genome and nuclei were 
stained with DAPI and then imaged by confocal microscopy. Relative size of fluorescent areas was 
measured using ImageJ software on >260 puncta from each conditon collected from three 
independent experiments. (B) Fixed cells were stained for VP2/3 and DAPI and imaged by 
fluorescence microscopy. Quantitation of relative fluorescence was performed on VP2/3 staining 
alone per cell using ImageJ software on a total of 200 cells from three independent experiments. 
Values are corrected total cell fluorescence to normalize for cell size. Statistical analysis in A and B 
was performed by independent samples T-test using GraphPad Prism software. Scatter plots show 
each data point value along with the mean and standard deviation. 
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beneath the outer layer of VP1 become exposed and available for interactions with antibodies 
(13). Since VP2/3 exposure represents virus that has at least entered the ER and undergone some 
disassembly, an important prerequisite for infection, we decided to use VP2/3 staining to observe 
the effects of ERAD inhibitors on viral disassembly. RPTE cells were infected at an MOI of 5 
IU/cell for 24 h, with epoxomicin added at 6 hpi, and fixed and labeled by indirect 
immunofluorescence against VP2/3. Compared to cells treated with DMSO, there was an 
increase in the intensity of VP2/3 staining in epoxomicin-treated cells (Figure 2.2B). Exposure of 
VP2/3 to antibody recognition was prevented by Brefeldin A (BFA) treatment, which inhibits ER 
trafficking of the virus (Figure 2.3). These data showed that proteasome inhibition does not 
inhibit uncoating, but seems to inhibit a later trafficking step such that it leads to some 
accumulation of uncoating intermediates.  
     We hypothesized that if the proteasome was acting in the ERAD pathway, and the ERAD 
pathway was necessary for BKPyV trafficking out of the ER, then proteasome inhibition may 
lead to incoming virus becoming trapped within the ER. To address the localization of partially 
uncoated virus with the ER, we co-stained for VP2/3 and the ER marker BiP. We found that in 
both untreated cells and epoxomicin-treated cells there was a range of colocalization between 
VP2/3 and BiP at 24 hpi, between 0 to 100% per cell, with the median colocalization in untreated 
cells at 82% (Figure 2.4A). Interestingly, however, we noticed that with epoxomicin treatment 
the pattern of both VP2/3 and BiP staining changed: distinct areas became devoid of BiP, VP2/3 
puncta became more localized to a juxtanuclear area, and median colocalization decreased to 
53% (Figure 2.4A). Interestingly, a number of reports have described an ER-associated quality 
control compartment (ERQC) where ERAD machinery becomes concentrated and substrates 
accumulate (22-24). This subcompartment is induced or exaggerated upon proteasome inhibition,  
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Figure 2.3: VP2/3 exposure is prevented when ER trafficking is inhibited. RPTE cells were 
infected at MOI 5 IU/cell, treated with BFA at 0 hpi or left untreated, and fixed at 24 hpi. Fixed 







Figure 2.4: BKPyV behaves like an ERAD substrate. RPTE cells were infected at MOI 5 IU/cell 
and fixed at 24 hpi. Fixed cells were stained for VP2/3 and the ER markers (A) BiP or (B) calnexin 
(cnx), and images taken by confocal microscopy. Arrowheads point to enlarged colocalized areas 
on the right. Colocalization of the individual VP2/3 puncta with calnexin or BiP was measured 
using MetaMorph software at the Center for Live Cell Imaging at the University of Michigan. 
Statistical analysis was performed as in Figure 2. The line represents the median colocalization for 
each condition. (C) RPTE cells were transfected with CD3δ-YFP and the media was changed at 12 
h post transfection. Transfected cells were infected at 5 IU/cell at 24 h post transfection, treated 
with 10 µM epoxomicin at 6 hpi, and fixed at 24 hpi (48 h post transfection). Fixed cells were then 





possibly to sequester potentially harmful unfolded and aggregation-prone proteins, and is 
positive for calnexin while often devoid of BiP (22-24). Therefore, we next looked at calnexin 
co-staining with VP2/3. In untreated cells, there was again partial colocalization between VP2/3 
and calnexin, with the median at 50%. In contrast to the pattern of VP2/3 and BiP colocalization, 
there was a significant increase in colocalization between VP2/3 and calnexin with epoxomicin 
treatment, where median colocalization increased to 75% (Figure 2.4B). These data showed that 
inhibition of the proteasome leads to relocalization of the virus to a calnexin-rich subregion of 
the ER that is deficient for the chaperone BiP.  
     Since the changing colocalization of BKPyV with BiP or calnexin suggested that BKPyV 
may be handled like an ERAD substrate, we asked whether the virus might colocalize with a 
commonly studied ERAD-targeted protein. We chose to examine CD3δ, a transmembrane 
protein subunit of the T cell receptor complex that is sent through the ERAD pathway when it is 
not assembled into the complex (25). RPTE cells were transfected with a CD3δ-YFP construct, 
then infected with BKPyV 24 hrs post transfection. Cells were fixed at 24 hpi and stained for 
VP2/3 and YFP to identify the transfected CD3δ. Confocal microscopy showed that VP2/3 and 
CD3δ co-localized within the ER at 24 hpi during normal infection, and remained associated 
with CD3δ in the presence of proteasome inhibition (Figure 2.4C). We could not quantify 
colocalization with CD3δ-YFP because transfection efficiency is extremely low in RPTE cells. 
Overall, these data suggest that BKPyV is shuttled to the same location with the ER as a 
substrate of the ERAD system, possibly due to interaction of BKPyV with the same recognition 
factors as a bona fide ERAD substrate.  
 
BKPyV enters the cytosol after ER trafficking occurs. 
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     The route taken by BKPyV into the nucleus after trafficking through the ER is unknown. The 
two possible pathways that have been proposed include crossing the ER membrane into the 
cytosol, from where the virus then undergoes active transport into the nucleus; or crossing the 
inner nuclear membrane directly into the nucleus without passing through the cytosol. To address 
the question of whether BKPyV traffics through the cytosol during infection, a biochemical 
assay was employed that allows for separation of a cellular lysate into a cytosol-containing 
fraction and a fraction including membrane-containing cellular components. Low percentage 
digitonin treatment selectively permeabilizes the plasma membrane by targeting the more 
cholesterol-rich membrane while leaving organelle membranes intact (26). This assay was 
previously used for measuring retro-translocation of ERAD substrates and is well-established as 
a means to address cytosolic entry of polyomaviruses (26, 27). 
      Employing this fractionation, we first asked whether we could see the appearance of 
monomeric VP1 capsid protein, which is a product of disulfide bond reduction in the ER, in the 
cytosol over time (9). To do so, we resolved the protein fractions using non-reducing SDS-
PAGE. In this assay, only VP1 monomers, pentamers, or oligomers from viral capsids that have 
undergone reduction or isomerization in the cell will migrate through the polyacrylamide gel 
matrix . We harvested infected cells under alkylating conditions, to prevent any post-harvest 
disulfide bond isomerization, at various time points after infection and isolated the cytosolic 
fraction via the digitonin permeabilization method. The integrity of the fractionation was 
confirmed by the absence of the ER protein PDI and presence of GAPDH in the cytosolic 
fraction (Figure 2.5A). We were able to detect monomer bands as well as higher molecular 







Figure 2.5: BKPyV enters the cytosol. (A) RPTE cells were infected at 5 IU/cell, harvested at the 
indicated time points under alkylating conditions, and fractionated into pellet and supernatant 
fractions. Fractions were separated by non-reducing SDS-PAGE and probed for VP1, ER marker 
PDI, and cytosolic marker GAPDH. One-third of the protein for the supernatant was loaded for 
the pellet fractions and the film was exposed for a shorter time. VP1 bands here include 
monomers and other higher-molecular weight species that have entered the non-reducing gel.(B) 
RPTE cells were infected at 5 IU/cell and treated at 6 hpi for two hours with 1.25 µg/ml BFA or 
left untreated, harvested at 16 hpi under alkylating conditions, then separated into pellet and 
supernatant fractions. Fractions were resolved by non-reducing SDS-PAGE and probed as above 
but with BiP as the ER marker. “VP1” here represents monomers that have entered the 
nonreducing gel. (C) RPTE cells were infected with biotinylated BKPyV at 5 IU/cell and 
harvested at 16 hpi under alkylating conditions, and assayed as in (A). The western blot was first 
probed with streptavidin-HRP to show the presence of biotinylated VP1 monomer (“biot-VP1”) 




supernatant beginning at approximately 18 hpi, with a slight increase in monomers over time 
(Figure 2.5A). This timing was consistent with the timing of ER trafficking of BKPyV. As 
expected, treatment with the ER trafficking inhibitor BFA reduced appearance of monomers in 
the cytosolic fraction (Figure 2.5B). Monomers were not completely absent in the cytosolic 
fraction most likely because we could only treat with BFA for 2 hrs before it became toxic. This 
may have allowed time for some virus to reach the ER early or for retrograde transport to regain 
function (28). The appearance of ER proteins (BiP or PDI) in the cytosolic fraction of BFA 
treated samples was seen consistently. This may be explained by the disruption of secretory 
pathways by BFA and the potential for these ER proteins to undergo export from the ER in small 
vesicles that may be present in the cytosolic fraction (29). 
     To ensure that the VP1 in the cytosolic fraction indeed represented incoming BKPyV rather 
than VP1 that was newly synthesized during infection, purified BKPyV was labeled with biotin. 
RPTE cells were infected as above and harvested after 24 hpi. The Western blot was probed with 
streptavidin-conjugated horseradish peroxidase and showed a band in the cytosolic fraction that 
ran at slightly reduced mobility than the VP1 in the unlabeled virus-infected fractions (Figure 
2.5C). We noted that biotinylation of VP1 prevented recognition by the VP1 monoclonal 
antibody. The presence of biotinylated VP1 in supernatant indicated that the protein visualized in 
the cytosolic fraction in Figure 2.5A is indeed from the infecting virus. These data together 
support our conclusion that the VP1 monomer visualized in  the cytosolic fraction is from 
incoming virus. 
 
Inhibition of ERAD does not prevent BKPyV entry into the cytosol. 
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     The previous experiments suggested that ERAD plays a role in BKPyV exit from the ER. We 
next wanted to test whether the proteasome inhibitor or ERAD inhibitor would therefore prevent 
entry of BKPyV into the cytosol, since ER exit and the proteasome are usually tightly linked (18, 
30). RPTE cells were infected at an MOI of 5 IU/cell and treated at 6 hpi with epoxomicin or 
Eeyarestatin I, harvested at 16 hpi, separated into pellet and cytosolic fractions, and proteins 
were resolved by non-reducing SDS-PAGE and probed for VP1. Unexpectedly, neither inhibitor 
prevented VP1 monomers from appearing in the cytosolic fraction (Figure 2.6A), and in fact 
treatment with epoxomicin led to an increase in the VP1 monomer signal in the supernatant 
fraction compared to cells treated with DMSO alone. We also saw a consistent increase in 
monomeric VP1 in the pellet fraction with epoxomicin treatment, while there was a decrease 
with Eeyarestatin I. Because of the discrepancy between VP1 monomers appearing in the cytosol 
and TAg production, these results suggest that cytosolic VP1 may not represent productive 
infection. 
     We also examined whether viral genomes were present within the cytosolic fraction and 
whether their appearance was sensitive to the inhibitors. Viral DNA was isolated from equal 
amounts of the supernatant fractions by proteinase K treatment followed by isolation of DNA on 
a PCR purification column. The proteinase K treatment was performed to release viral genomic 
DNA that may be still associated with partially disassembled capsids. In agreement with VP1 
monomer levels, there was much less viral DNA in the cytosol of infected cells treated with BFA 
(Figure 2.6B). As opposed to the increase in VP1 monomers in the cytosol of epoxomicin treated 
cells, however, there was approximately two-fold less viral DNA. In the cytosol of cells treated 




Figure 2.6: ERAD inhibition does not prevent cytosolic entry of BKPyV. (A) RPTE cells were 
infected with BKPyV at 5 IU/cell at 4°C for 1 h and treated with 10 µM epoxomicin (Epox), 10 
µM Eeyarestatin I (EerI), or DMSO at 6 hpi, harvested at 16 hpi under alkylating conditions, 
then separated into pellet and cytosolic fractions and assayed as in Figure 4. (B) BKPyV 
genomic DNA isolated from treated and untreated supernatant fractions was measured by QPCR 
and normalized to untreated levels. Averages from three independent experiments are shown 
with error bars representing standard deviation. A one-tailed T-test was performed and the 
significance for BFA treatment was P=0.0008 and epoxomicin treatment was P=0.03. 
Eeyarestatin I treatment did not cause a significant decrease in DNA. 
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Trafficking requirements differ between viruses and cell types. 
     Recent studies have shown that trafficking from the ER to the cytosol of the closely related 
polyomavirus, SV40, is blocked when the proteasome or ERAD are inhibited, based on 
appearance of SV40 capsid proteins in the cytosol (15, 16, 27). Since our results with BKPyV in  
RPTE cells differ from what has been published for SV40 in CV-1 cells, we first decided to 
examine the trafficking of BKPyV in CV-1 cells. To improve the infectivity of BKPyV, we first 
incubated CV-1 cells with the BKPyV receptor GT1b. Cells were then infected with BKPyV, 
harvested at 16 hpi under alkylating conditions, and fractionated into pellet and supernatant 
fractions. Interestingly, there seemed to be little to no effect of epoxomicin treatment on the 
appearance of VP1 monomers in the cytosol, and BFA treatment led to a consistent decrease in 
VP1 monomers (Figure 2.7A). Next we looked at viral DNA levels in the cytosol using qPCR as 
above. Inhibition of viral genomes from entering the cytosol by both BFA and epoxomicin was 
similar to what was seen in RPTE cells (Figure 2.7B).  
     Next we wanted to evaluate the effect of our inhibitors on SV40 infection in both CV-1 cells 
and RPTE cells. First, we determined whether the inhibitors could prevent infection of CV-1 
cells. To allow productive infection of RPTE cells with SV40, cells were incubated with the 
SV40 receptor, ganglioside GM1, for 24 h before infection (3). Interestingly, epoxomicin 
treatment strongly inhibited infection in both cell types, as assayed by TAg expression, but 
Eeyarestatin I only inhibited infection of RPTE cells (Figure 2.7C). As Eeyarestatin I targets 
p97, and protein expression levels can differ between cell types (31), it may be that there is an 
indirect effect of p97 inhibition on virus trafficking in RPTE cells, whereas the trafficking 




Figure 2.7: Cell type-specific requirements for polyomavirus trafficking. (A) CV-1 cells were infected with 
BKPyV and treated with BFA, epoxomicin (Epox), or DMSO as in Figure 5A. Pellet and supernatant fractions 
were separated and assayed as in Figure 4. (B) BKPyV genomic DNA from the CV-1 supernatant fractions was 
quantified by QPCR and represented as in Figure 4B. A T-test determined significance of the decrease in BFA 
treatment to be P=0.02 and epoxomicin treatment to be P=0.02. (C) RPTE or CV-1 cells were inoculated with 5 
IU/cell SV40 at 4°C for 1 hr then moved to 37°C and incubated in the presence of 10 µM epoxomicin (Epox), 
10 µM Eeyarestatin I (EerI), or DMSO. RPTE cells were incubated for 24 h with 3.2 µM ganglioside GM1 prior 
to infection. Whole cell lysates were harvested at 24 hpi, resolved by reducing SDS-PAGE, blotted, and probed 
for TAg. (D) As in 4D, RPTE cells were infected with 5 IU/cell SV40 in the presence of 1.25 µg/ml BFA, 10 
µM epoxomicin (Epox), 10 µM Eeyarestatin I (EerI), or DMSO. Proteins were harvested under alkylating 
conditions at 10 hpi and fractions analyzed as in Figure 4. Western blot was probed for SV40 VP1 monomers, 
PDI, and GAPDH. (E) SV40 genomic DNA was isolated and quantified by QPCR. Values for each condition 
were normalized to untreated levels and the averages from three independent experiments are represented with 
error bars showing the standard deviation. A T-test was performed for each condition and the significance in 
CV-1 cells was P=0.008 for BFA treatment, with no significant decrease for epoxomicin treatment. In RPTE 




Eeyarestatin I on SV40 TAg expression suggest that requirements for infection vary between cell 
types.  
     Next we wanted to address SV40 cytosolic trafficking in the RPTE cell system. After 
incubation with GM1, RPTE cells were infected with SV40 at an MOI of 5 IU/cell and 
fractionation was performed at 10 hpi to separate membrane bound organelles and cytosolic  
components. This infection was shorter because SV40 traffics more rapidly than BKPyV, with 
TAg expression detectable at 14 hpi by Western blot (27). As shown in the top panel of Figure 
2.7D, epoxomicin inhibited SV40 VP1 monomers from entering the cytosol of CV-1 cells, as has 
been previously reported (15, 27). However, appearance of cytosolic SV40 VP1 was not 
inhibited in RPTE cells: VP1 monomers increased in the cytosolic fraction when cells were 
treated with epoxomicin (Figure 2.7D, bottom panel) in the same way as seen with BKPyV (see 
Figure 2.6). For both cell types, Eeyarestatin I prevented SV40 VP1 monomers from appearing 
in the cytosol, which was interesting since the drug does not inhibit infection in CV-1 cells. In 
RPTE cells the SV40 VP1 monomers accumulated in the pellet under epoxomicin treatment and 
decreased in the pellet with Eeyarestatin I treatment, while in CV-1 cells there was not a 
noticeable change in VP1 monomer levels of the pellet. BFA strongly inhibited VP1 from 
appearing in the pellet in CV-1 cells, however. Finally, we looked at SV40 DNA levels in the 
cytosolic fractions of both CV-1 and RPTE cells. Although the appearance of VP1 protein within 
the cytosol was affected differently by epoxomicin and Eeyarestatin I, we saw a similar decrease 
in cytosolic viral genomes (Figure 2.7E). Together these data suggest that the appearance of VP1 
protein within the cytosol does not correlate with viral genomes, and perhaps the appearance of 




     Uncovering the mechanism of virus entry and trafficking is important for understanding viral 
pathogenesis and identifying antiviral targets. Furthermore, since viruses are obligate 
intracellular pathogens, studies of host-virus interactions often elucidate unknown intracellular 
pathways and illuminate known pathways, adding to the understanding of basic cellular biology. 
Previous findings implicated components of the ERAD pathway, including the proteasome, 
during early events of polyomavirus infection (9, 15, 16, 27). The possibility of ERAD 
involvement led us to pursue the role of the proteasome during BKPyV infection and whether it 
was acting in the context of the ERAD pathway and possibly in viral trafficking out of the ER. In 
this study we have found that BKPyV requires a functional proteasome and ERAD pathway 
during entry, and we also found that inhibition of these cellular mechanisms leads to a 
sequestration of BKPyV within an ER-quality control subcompartment. Additionally, we have 
found that both BKPyV and SV40 capsid proteins and DNA reach the cytosol during infection in 
both RPTE cells and CV-1 cells. Interestingly, we have found that a number of differences exist 
between cell types and between viruses, and that measurement of VP1 monomers in the cytosol 
is not a reliable assay for viral cytosolic trafficking.  
     We hypothesized that proteasome function was required during BKPyV entry, and we found 
that the proteasome played a role at an early point during infection by examining sensitivity to 
epoxomicin treatment. Proteasome function was required before 18hpi, which is a timepoint after 
ER trafficking as determined previously by treatment with the retrograde trafficking inhibitor 
BFA (9). In addition, we know that epoxomicin does not inhibit TAg gene transcription when 
TAg is expressed from a transfected plasmid (Figure 2.8). A role for the ERAD pathway was 




Figure 2.8: Expression of TAg is not directly inhibited by epoxomicin treatment. RPTE 
cells were transfected with recircularized TU genome and treated with epoxomicin or 
DMSO immediately after transfection. RNA was harvested at 24 h after transfection, and 





expression when added before 18hpi. We also found that reduction of p97 protein, the target of 
Eeyarestatin I, by siRNA led to a reduction in infection (Figure 2.9); however, cytotoxic effects 
were observed in the p97 knock down cells, causing us to view this result with caution.  
     Since inhibition of the ERAD pathway abrogated infection, we were interested in visualizing 
where the blockage was occurring within the cell. We hypothesized that if BKPyV was unable to 
traffic to the nucleus without the ERAD pathway, we might see an accumulation of virus outside 
the nucleus. In support of this, we saw a reproducible increase in the amount of virus genome 
accumulating, much of it in a juxtanuclear position. We then visualized partially uncoated virus 
particles by staining for the minor capsid proteins VP2/3, which become available to antibody 
recognition only after capsid disassembly begins. Interestingly, we observed a change in the 
morphology of the ER following epoxomicin treatment, as ER-resident proteins BiP and 
calnexin showed different staining patterns, suggesting their partitioning to different ER 
subdomains (Figure 2.4). BKPyV localization within the ER also changed, colocalizing more 
with calnexin under proteasome inhibition than in untreated conditions (Figure 2.4B). A number 
of recent studies describe an ERQC subcompartment that is enriched in certain ERAD and 
ERQC factors including calnexin, but is devoid of other ER proteins such as BiP (22-24). This 
subcompartment is exaggerated upon proteasome inhibition, and ERAD factors and substrates 
such as CD3δ accumulate within this area (23). If BKPyV is handled like an ERAD substrate, an 
increase in the concentration of viral disassembly factors within the ERQC compartment may 
explain the accumulation of partially disassembled virus in the epoxomicin-treated cells, as 
shown by the increase in total VP2/3 immunofluorescence. In further support of BKPyV acting 
as an ERAD substrate, we detected colocalization between BKPyV and CD3δ, and this 




Figure 2.9: Knockdown of p97 reduces infection. RPTE cells were transfected with non-
targeting (NT) or p97 siRNA for 2 days, then infected with BKPyV at MOI 1. Whole cell 
lysates were harvested at 24 hpi and resolved by SDS-PAGE and probed for TAg, p97, and 




     Recent findings with SV40 support the role of ER-localized ERAD components during 
polyomavirus passage into the cytosol. These factors include DnaJ chaperone family proteins 
and the abundant ER chaperone BiP, all discovered in unbiased siRNA screens for modulators of 
SV40 infection (16). These factors were shown to be necessary after partial disassembly and 
VP2/3 exposure but before cytosolic entry of SV40. Another ERAD protein, Bap31, was also 
found to be necessary for entry of SV40 into the cytosol, and these authors found that an 
interaction between VP2 and Bap31 was necessary for cytosolic entry (15). Interestingly, Bap31 
has been described as a shuttle for ERAD substrates to the ERQC compartment (22). Proteasome 
inhibition may increase the concentration of other ERAD substrates, titrating Bap31 away from 
the virus and thus decreasing ER exit of the virus particle. In addition, this may cause BiP to 
move away from the ERQC compartment and BKPyV. 
     In support of a role for an ER-to-cytosol entry step, we detected VP1 monomers in the cytosol 
at a timepoint that follows ER trafficking. Detection of VP1 protein by non-reducing SDS-PAGE 
supports the conclusion that the capsid protein in the cytosol has first passed through the ER 
where it has undergone reduction and/or isomerization by oxidoreductases, especially since VP1 
monomers are diminished in the presence of BFA. The amount of VP1 is just above the limit of 
detection by Western blot, suggesting that a very low percentage of input virus particles reach 
the cytosol. Because of detection issues, we were not able to use VP2/3 as a readout for virus in 
the cytosol by Western blot.  
     The appearance of BKPyV capsid protein in the cytosol, along with ERAD involvement, 
points to a co-opting of the ER-to-cytosol retrotranslocation pathway by the virus. Surprisingly, 
however, we were not able to prevent appearance of VP1 monomers with ERAD inhibition by 
epoxomicin or Eeyarestatin I in RPTE cells. Rather, we saw an accumulation of VP1 monomers 
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in the cytosol in the presence of epoxomicin, and no difference with Eeyarestatin I. Since the 
ERAD inhibitors prevent infection as measured by TAg expression, these data seemed to go 
against the hypothesis that inhibition of the proteasome and ERAD pathway would prevent 
trafficking of BKPyV out of the ER. For this reason we asked whether the viral genome was also 
reaching the cytosol, since transport of the viral genome to the nucleus is necessary in any 
potential productive pathway. Interestingly, in the presence of epoxomicin, there was a decrease 
in BKPyV genomes present in the cytosol. These changes in viral DNA levels within the cytosol 
support the possibility that some infectious virus particles may be trapped within the ER when 
proteasome function is inhibited, even though VP1 protein can still enter the cytosol. It may be 
that retro-translocation of VP1 monomers, disassembly by-products, normally occurs 
independent of proteasome function, followed by proteasome degradation, allowing for the 
accumulation we see in the presence of inhibitor. This scenario does not seem to occur during 
SV40 infection. The inconsistent effects of Eeyarestatin I treatment on viral DNA levels in the 
cytosol may suggest that the p97 inhibitor is targeting other trafficking pathways besides ERAD 
that lead to inhibition of TAg expression. 
     A number of recent studies have evaluated ER-to-cytosol trafficking of SV40 based on the 
presence of capsid protein VP1 in the cytosol. Our studies, however, seem to suggest that VP1 
and viral genomes may represent different events or pathways, separate or overlapping. 
Importantly, these events differ between cell types and even between viruses. Compared to 
infected RPTE cells, BKPyV-infected CV-1 cells show a different phenotype of VP1 entry into 
the cytosol, where there seems to be no difference between epoxomicin-treated and untreated 
cells. And as has been previously published (15, 27), SV40 VP1 does not enter the cytosol in 
epoxomicin-treated CV-1 cells, while in RPTE cells it undergoes the same accumulation as 
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BKPyV. While the variation in levels of cytosolic VP1 in the presence of trafficking inhibitors 
suggests that virus trafficking may differ between cell types, the effect on cytosolic viral 
genomes is similar in each cell type and between viruses.  
     The level of viral genomes in the cytosol with epoxomicin treatment ranged from about 50% 
of untreated for BKPyV to about 80% for SV40. Although an inhibitory effect of epoxomicin 
treatment is consistent with proteasome function being required for ER exit, the fact that TAg 
expression is much more strongly inhibited in the presence of the inhibitors than the cytosolic 
entry of viral DNA raises the question of whether the viral genomes in the cytosol are part of the 
infectious pathway. If cytosolic trafficking is a productive pathway, perhaps the proteasome acts 
after transport of the infectious particle across the ER membrane. On the other hand, our results 
could be explained by non-specific effects of proteasome inhibition: i.e., aggregates or other 
misfolded obstructions within the ER lumen would prevent effective passage of virus through the 
ER to its next proper destination. This nonspecific effect is supported by the change in ER 
morphology and accumulation of disassembled virus that we observe under proteasome 
inhibition. This result is consistent with a possible model in which the cytosolic viral 
components represent a non-productive or dead-end pathway. Originally, inhibition of SV40 
VP1 from entering the cytosol by epoxomicin in CV-1 seemed to support cytosolic trafficking as 
a productive pathway since it correlated with a block in TAg expression. However, SV40 VP1 
monomers are also inhibited by Eeyarestatin I even though the drug does not inhibit overall 
infection. Moreover, in RPTE cells, VP1 monomers from both viruses can enter the cytosol 
under either drug treatment, while TAg expression is prevented with both treatments. 
     This study raises an interesting question about differences in the biology of the cell types used 
for studying polyomavirus entry. It is well accepted that protein expression levels (31), cell cycle 
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regulation (32), and other aspects of cell biology differ between cell types, and these 
discrepancies should be considered when studying cell biology of a viral infection. We also 
cannot rule out species-specific behavior of cells. The experiments in this report were performed 
in primary cells that are a natural host cell of BKPyV, and are more likely to represent the 
biology of BKPyV lytic infection in the natural host.  
     Previous results also questioned whether SV40 travels through the cytosol as its productive 
route of infection. Some studies have shown transient disturbances in the nuclear membrane that 
occur around the time of nuclear entry (6, 33), suggesting that trafficking from the ER to the 
nucleus occurs by crossing the inner nuclear membrane through temporary disruption in the lipid 
bilayer. This model cannot yet be ruled out to describe BKPyV nuclear entry. One interesting 
thing to consider is the hydrophobic nature of the minor capsid proteins. Both VP2 and VP3 of 
SV40 have been previously shown to have membrane lytic properties and to be able to at least 
partially insert into ER membranes (34). If the virion can penetrate the ER membrane to enter the 
cytosol, then it is reasonable to believe that it may also be able to penetrate the inner nuclear 
membrane to gain direct access to the nucleus. Penetration may be limited to a membrane that is 
contacting the cytosol if specific cytosolic proteins are required for the process. Also, even 
though there is no precedent for an ERAD substrate to be translocated into the nucleus, an inner 
nuclear membrane–localized ERAD E3 ligase has been identified in yeast and may suggest a 
way for the ERAD pathway to be combined with direct nuclear entry (35). Another possibility 
that would further support cytosolic trafficking as a productive pathway is if a disassembly step 
occurs within the cytosol. A better understanding of BKPyV disassembly will be required before 
the process of nuclear entry can be fully elucidated. 
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     In conclusion, this study demonstrates involvement of the ERAD pathway during BKPyV 
entry and infection, and provides evidence that there are complex interactions between 
polyomaviruses and the host cell machinery. Additionally, the data presented here regarding the 
observed cell type differences in polyomavirus trafficking call for re-examination of the current 
paradigm for cytosolic trafficking of polyomaviruses. This study emphasizes the relevance of 
primary cell models of infection and provides avenues for further investigation to determine how 
polyomaviruses enter the cell nucleus.  
 
Materials and Methods 
Cell Culture. RPTE cells were grown in renal epithelial basal growth medium (REGM) with 
SingleQuots Bulletkit from Lonza at 37°C and 5% CO2 and passaged up to six times as 
previously described (36). The CV-1 cell line (African Green Monkey Kidney Cells, ATCC) was 
grown in Dulbecco’s modified Eagle’s medium with 10% heat-inactivated fetal bovine serum 
(HyClone), 100 U/ml penicillin, and 100 μg/ml streptomycin (Cambrex).  
 
Transfections. The CD3δ-YFP plasmid was obtained from Addgene, Cambridge, MA (plasmid 
11951) (37). Transfection complexes were prepared according to manufacturer’s instructions, 
using TransIT
®
-LT-1 (Mirus) reagent at a 1:6 ratio of DNA-to-transfection reagent. Cells were 
seeded on glass coverslips in a 12 well plate and transfected with 0.5 µg plasmid per well at 
approximately 70-80% confluency. Media was changed 12 hours post transfection and infections 




Infections. Purified BKPyV (TU variant) was propagated and purified as previously described 
(36). SV40 was a gift from Billy Tsai (University of Michigan). The viral titer was measured by 
fluorescence focus assay as previously described (9). Infections were performed when RPTE 
cells or CV-1 cells were approximately 70-80% confluent. Cells were first pre-chilled for 15 
minutes at 4°C. Purified virus was mixed with cold REGM or serum-free DMEM for RPTE cells 
or CV-1 cells, respectively, and virus was bound for one hour at 4°C. Cells were washed once 
with cold media and then switched to warmed full media and incubated at 37°C until the desired 
time. For ganglioside receptor pre-treatment, cells were incubated 24 hrs before infection with 
either GM1 or GT1b, then washed 3 times with media. Biotinylated BKPyV was prepared by 
incubating virus particles with EZ-Link Sulfo-NHS-LC-Biotin (Thermo), according to the 
manufacturer’s instructions. 
 
Drug Treatments. Epoxomicin (Sigma, Enzo Lifesciences) and Eeyarestatin I (Santa Cruz 
Biotech) were each dissolved in DMSO and used at 10 µM. Brefeldin A (Sigma) was dissolved 
in ethanol and used at 1.25 µg/ml. A WST metabolic assay (Roche) was used to ensure that drug 
treatments did not cause significant cytotoxicity under the conditions used. Ganglioside GM1 or 
GT1b (Santa Cruz Biotech) was reconstituted in water and used at 3.2 µM. 
 
Preparation of cell lysates. Whole cell protein lysates were harvested in E1A buffer (50mM 
HEPES pH 7, 250 mM NaCl, 0.1% NP40, with protease inhibitors 5 µg/ml PMSF, 5 µg/ml 
aprotinin, 50 mM NaF, 0.2 mM Na-orthovanadate, and 5 µg/ml leupeptin added right before 
use). Protein concentrations were determined using a Bradford assay. For cytosolic fractionation, 
a 100 mm plate or 2 wells of a 6-well plate cells were infected with virus at an MOI of 5 
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infectious units per cell (IU/cell) with BKPyV or SV40. Cells were harvested at 16 hpi for 
BKPyV and 12 hpi for SV40 by treating with 0.25% trypsin for approximately 1 minute or until 
cells detached from the plate. Trypsin was inhibited with equal volume 1 mg/ml soybean trypsin 
inhibitor, and cells were collected in 4 ml cold PBS. Cells were pelleted at 300 x g for 5 min at 
4°C and then resuspended in 1 ml 20 mM N-Ethylmaleimide (NEM) (Sigma) in PBS for 45 min 
on ice. After alkylation, cells were again pelleted and resuspended in 100 µl of 0.01% digitonin 
(for RPTE cells) or 0.05% digitonin (for CV-1 cells) in HCN buffer (150 mM HEPES pH 7.5, 50 
mM NaCl, 2 mM CaCl2, 20 mM NEM and protease inhibitors at 5 µg/ml PMSF, 5 µg/ml 
aprotinin, 50 mM NaF, 0.2 mM Na-orthovanadate, 5 µg/ml leupeptin added right before use) for 
10 min on ice. The cytosolic fraction was separated from the pellet fraction by centrifugation at 
16,000 x g, 10 min, 4°C. The supernatant (cytosolic) fraction was removed and the pellet was 
washed with 500 µl 1x PBS. The pellet fraction was solubilized by resuspension in 100 µl of 
E1A lysis buffer, and then clarified by centrifugation at 16,000 x g, 5 min. To isolate either 
BKPyV or SV40 genomic DNA from cytosol-enriched supernatant fractions, equal amounts of 
lysate based on protein concentration (150 ng) from each sample was treated with 5 µg 
proteinase K (Qiagen) for 1 hr at 37°C. DNA was then isolated from the samples by PCR 
Purification kit (Qiagen).   
 
Western Blots. Equal amounts of protein were resolved by SDS-PAGE, (8% for TAg, 10% for 
all other proteins), under reducing or nonreducing conditions and transferred overnight onto a 
nitrocellulose membrane at 60 V by wet transfer. Membranes were blocked in 2% nonfat dry 
milk in PBS containing 0.1% Tween 20 (PBS-T). Primary and secondary antibodies were diluted 
in 2% milk in PBS-T as follows: TAg was detected with mouse monoclonal antibody pAb416 
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(38) at 1:1000; BKPyV VP1 was detected by mouse monoclonal antibody P5G6 at 1:5000; ER 
proteins were detected by mouse anti-BiP (BD Biosciences) at 1:1000 and rabbit anti-PDI (Enzo) 
at 1:2000; SV40 VP1 was detected by mouse monoclonal anti-VP1 (a gift from Billy Tsai, 
originally from Dr. W. Scott) at 1:2000; rabbit anti-β-actin (Cell Signaling) was used at 1:10,000 
and mouse anti-GAPDH (Abcam) was used at 1:5000; HRP-conjugated ECL™ anti-mouse and 
anti-rabbit IgG secondary antibodies (GE) were used at 1:2000- 1:5000; streptavidin-conjugated 
horseradish peroxidase (GE) was used at 1:1000. 
 
Flourescence In Situ Hybridization (FISH). RPTE cells were grown on coverslips and infected 
as described above, and fixed at 24 hpi using cold 95% EtOH/ 5% acetic acid. Coverslips were 
treated with RNAse for one hour at 37°C to avoid any RNA background staining. Coverslips 
were then pre-hybridized by incubation in hybridization buffer (50% formamide, 10% dextran 
sulfate, 4% SSC) for at least 30 min at 37°C. The fluorescently labeled DNA probe against the 
viral genome was prepared using nick translation kit (GE) with Cy3-dCTP and pBR322 plasmid 
containing the TU BKPyV genome. Unincorporated nucleotides were filtered using a Bio-Rad 
Quickspin column. The hybridization step was performed by first diluting the probe in 
hybridization buffer, denaturing the probe and coverslips at 95°C for two minutes, and 
immediately incubating the denatured coverslips with the denatured probe overnight at 37°C in a 
humidified chamber. The next day, the coverslips were washed 1x with 2x SSC at 60°C, 1x with 
2x SSC at room temperature, and 1x with 1x PBS, at room temperature. Coverslips were then co-





Immunofluorescence microscopy. At the desired time post infection, cells were fixed and 
permeabilized with 95% ethanol/ 5% acetic acid. Coverslips were blocked with 5% goat serum 
in PBS and then probed with primary antibody diluted in 5% goat serum. Antibodies used were 
mouse anti-calnexin (BD Biosciences) at 1:40, mouse anti-BiP (Santa Cruz) at 1:200, and mouse 
anti-GFP at 1:100 (Santa Cruz) dilutions. Anti-VP2/3 was raised by Bethyl Laboratories, Inc. 
against the peptide sequence CKTGRASAKTTNKRRSRSSRS and obtained as affinity-purified 
antibodies after processing from hyperimmune sera from immunized rabbits. Secondary 
antibodies Alexa-Flour
®
 594 goat anti-rabbit IgG or Alexa Fluor
®
 488 goat anti-mouse 
(Invitrogen) were used at a 1:200 dilution. Coverslips were mounted onto slides using Prolong 
Gold Antifade with DAPI (Invitrogen). Imaging was done on a Zeiss LSM 510-META Laser 
Scanning Confocal Microscope using a C-Apochromat 63x objective and 1.0 µm optical section 
at the University of Michigan Microscopy and Imaging Analysis Laboratory. 
 
Quantitative Polymerase Chain Reaction (qPCR). Before qPCR, samples were diluted 100-
fold. Primers used to quantify BKPyV were 5’ TGTGATTGGGATTCAGTGCT 3’ and 5’ 
AAGGAAAGGCTGGATTCTGA 3’, and to quantify SV40 were 5’ 
AAGCAAAGCAATGCCACTTT 3’ and 5’ CACTGCAGGCCAGATTTGTA 3’ (Invitrogen). 
Both pairs amplify a region of the TAg open reading frame.  
 
Notes  
     This work was reprinted and modified with permission from Bennett, S.M., Jiang, M, 
Imperiale, M.J, Role of Cell-Type Specific ER-Associated Degradation in Polyomavirus 
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Trafficking, J Virol, 2013, 87(16): 8843-8852. Mengxi Jiang helped with experimental design 
and performed initial time-course and imaging experiments with proteasome inhibitors.  
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The nuclear localization signal on VP2/3 is important for BK Polyomavirus nuclear entry 
 
 
     BK Polyomavirus (BKPyV) is a small nonenveloped virus that is ubiquitous in the human 
population and can cause severe disease in immunocompromised patients. It is believed that 
BKPyV traffics through the ER and then into the cytosol during entry in renal proximal tubule 
epithelial cells. It is unclear, however, how the virus reaches the nucleus. In this study, we 
elucidate a role for the nuclear localization signal located on the minor capsid proteins VP2 and 
VP3 during entry. We show that site directed mutagenesis of a single lysine in the basic region of 
the C-terminus of the minor capsid proteins will abrogate their individual nuclear localization, 
and the analogous mutation in the genome caused attenuation of infectivity based on an entry 
defect sometime after ER trafficking. The role of the nuclear localization signal (NLS) in the 
individual minor capsid proteins was addressed using pseudovirions. Mutation of the VP3-NLS 
led to an attenuated phenotype in 293TT cells, but not in RPTE cells. Overall these data are the 
first to show the importance of the NLS of the minor capsid proteins during BKPyV infection. 
 
Introduction  
     BK Polyomavirus (BKPyV) is a widespread human pathogen that establishes a persistent 
subclinical infection in the majority of the population. However, reactivation can occur in imm
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unosuppressed individuals, particarly bone marrow and kidney transplant patients (1). Currently 
there are no specific antivirals and the only treatment is palliative or the reduction of 
immunosuppression, respectively, leaving renal transplant patients open to organ rejection. 
Understanding the life cycle of the virus within the host will provide much needed information 
for future development of targeted therapies to lessen BKPyV reactivation and disease. 
     The BKPyV particle is small, nonenveloped, and consists of three structural proteins, 
including the major capsid protein VP1 and minor capsid proteins VP2 and VP3. The structural 
proteins encapsidate the 5 Kb circular double stranded DNA genome, which takes the form of a 
minichromosome associated with histones (2). The outer layer of the particle is made up of 72 
VP1 pentamers stabilized by intermolecular disulfide bonds (3). Associated with each pentamer 
is approximately one molecule of either VP2 or VP3, which are not exposed to the surface of the 
particle until disassembly begins within the endoplasmic reticulum (ER) of the host cell. VP2 
and VP3 are expressed from the same reading frame and share an identical C-terminus, but VP2 
contains a unique N-terminal sequence that can be myristoylated (2). Our lab has previously 
shown in renal proximal tubule epithelial (RPTE) cells that BKPyV reaches the ER at ~8 – 10 
hpi (4), then traffics through the cytosol ~16 hpi (5), followed by nuclear entry and early gene 
expression beginning ~24 hpi (6). Data suggest that BKPyV and other polyomaviruses exit the 
ER to reach the cytosol by using components of the ER-associated degradation pathway. It is 
currently unknown how the virus reaches the nucleus from the cytosol. It is reasonable to 
hypothesize that the partially disassembled virus could enter the nucleus through the nuclear 
pore, since disassembly would allow the particle to be small enough for import through the pore.  
     Previous studies have provided conflicting evidence for the nuclear entry mechanism of 
polyomaviruses. Studies from Nakanishi et al. have shown an interaction between importins α 
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and β and SV40 genomes in the cytosol, implying the use of the canonical nuclear import 
pathway for nuclear entry of SV40 (7, 8). Additionally, it was shown that the basic amino acids 
in the C-terminus of VP2/3 are necessary for the interaction with the importins, suggesting that 
nuclear entry of SV40 is mediated by interactions between a nuclear localization signal (NLS) on 
the minor capsid proteins VP2/3 and the canonical nuclear import machinery, which would 
mediate import through the nuclear pore complex (7, 8). However, studies by Butin-Israeli et al. 
have provided evidence that infection may lead to breakdown of the nuclear lamina and 
disruption of the nuclear envelope, allowing the virus to pass from the ER lumen directly into the 
nucleus (9). 
     In this study we have evaluated the role of the nuclear localization signal of the minor capsid 
proteins during entry of BKPyV. We have found that a vital lysine in VP2 and VP3 is important 
for localization to the nucleus of the BKPyV minor capsid proteins, and that mutation of this 
lysine in the virus attenuates entry at a point after ER trafficking. Additionally, we have found 
that the NLS of VP3 is more important during infection than the NLS of VP2. These findings 
provide more details of the trafficking route of BKPyV, and they provide a model where 
polyomavirus enters the nucleus from the cytosol through the nuclear pore, using the NLS of 
VP3 as the import signal. 
 
Results  
Lysine 319 on VP2 and Lysine 200 on VP3 are critical for nuclear localization of the minor 
capsid proteins.  
     The cellular localization of the minor capsid proteins of BKPyV, when expressed 
individually, has not been determined to date. Because BKPyV VP2 and VP3 share homology 
75 
 
with SV40, especially in the C-terminal basic amino acids determined to be important for nuclear 
localization of the SV40 proteins (10, 11) (Figure 3.1A), we hypothesized that VP2 and VP3 of 
BKPyV would also possess a nuclear localization signal that mapped to these residues. To test 
this, we expressed VP2 or VP3 alone in RPTE cells by transfection with an expression plasmid. 
In RPTE cells, both VP2 and VP3 showed localization in the nucleus, colocalizing with cellular 
DNA as measured by DAPI staining (Figure 3.1B, first columns). We next wanted to determine 
the amino acids necessary to confer this nuclear localization. It has been previously shown that 
the Lysine 320 on SV40 VP2 (and the same amino acid on VP3) was vital for nuclear 
localization of the SV40 minor capsid proteins (11). Therefore, we targeted the conserved lysine 
on BKPyV – 319 of VP2 and 200 of VP3 – for mutagenesis (Figure 3.1A, arrow). Site-directed 
mutagenesis was used to convert the lysine to a threonine, and the mutant constructs were 
transfected into RPTE cells to test localization of the proteins. Indeed, VP2K319T and 
VP3K200T no longer localized to the nucleus (Figure 3.1B, second columns). 
     For SV40, it had been shown that co-expression of VP1 would allow for nuclear import of 
nuclear localization-defective minor capsid proteins (12, 13). To test whether this was the case 
for BKPyV as well, we cotransfected a VP1 expression vector with each of the VP2K319T and 
VP3K200T expression vectors. The presence of VP1 led to nuclear localization of both 
VP2K319T and VP3K200T (Figure 3.1B, third columns). This observation suggests that the 
nuclear localization signal on VP1 allows for import of the VP1-VP2 or VP1-VP3 complex. 
These results suggest that assembly of capsids, which takes place in the nucleus, should not be 
affected by the presence of a mutation in the minor capsid protein NLS. 
 





Figure 3.1: Lysine 319 in VP2 and 200 in VP3 is required for nuclear localization. (A) 
BKPyV, JC Polyomavirus (JCPyV), SV40, and mouse polyomavirus (mPyV) C-terminal 
sequences were aligned to compared homology.  The lysine we chose to mutate is indicated 
with the arrow. (B) RPTE cells were transfected with a VP2 expression plasmid (left) or 
VP3 expression plasmid (right), the plasmid with a point mutation, or both the mutant and 
VP1 expression plasmids, then fixed at 24 h post transfection. VP2 and VP3 were stained 
with red, VP1 with green, DAPI in blue.  
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     To evaluate the role of the minor capsid protein NLS during infection, a point mutation was 
created in the viral genome to convert the vital lysine of VP2 and VP3 to a threonine as was done  
in the expression plasmids. The mutation was created in both the Dunlop and TU variant genetic 
backgrounds. The genome was excised from the plasmid, and recircularized mutant and wild 
type genomes were transfected into RPTE cells. The transfected cells were harvested and used as 
a crude stock of virus to infect a new set of RPTE cells. Those infected RPTE cells were then 
harvested after two weeks and the quantity of viral genomes in the crude stock was measured 
using qPCR. Of note, there were similar levels of viral genomes in both purified and mutant 
stocks of virus. PCR and sequencing was performed to ensure that the mutation was still present 
in the crude stocks (data not shown).  
     To test infectivity of the mutants, equal numbers of genomes were used to infect RPTE cells. 
Lysates were collected at 24 hpi, resolved by SDS-PAGE, and probed for the early protein large 
T Antigen (TAg). Compared to wild type viruses, mutant Dunlop and TU were both inhibited in 
TAg expression (Figure 3.2A), suggesting a possible defect in entry.  
     To assess whether early entry events were disrupted by the introduction of the mutation, we 
evaluated disassembly and ER trafficking. As the virus traffics through the ER, the disulfide 
bonds between the VP1 pentamers become reduced. The disassembly process can be detected 
beginning at about 12 hpi and shows increasing levels of VP1 monomers and oligomers over 
time (4). This can be detected by SDS-PAGE under non-reducing conditions, as compared to 
virus that has not begun disassembly. To compare mutant and wild type virus, RPTE cells were 
infected with equal genomes and harvested at 0 hpi and 24 hpi under alkylating conditions. The 
lysates were run under non-reducing conditions and probed for VP1. At 0hpi, there is an absence  
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Figure 3.2: The minor capsid protein NLS is important during infection of RPTE cells. (A) RPTE 
cells were infected with 10 thousand genomes/cell of mutant or wild-type virus in the Dunlop 
(dun) or TU backgrounds then harvested at 24 hpi, run on SDS-PAGE and the western blot was 
probed for TAg. The TAg levels from three independent experiments were measured using the 
Odyssey system and displayed on the graph (below). (B) RPTE cells were infected with 1000 
genomes of mutant or wild type purified Dun virus and then harvested under alkylating conditions 
at 0 hpi or 24 hpi, and resolved by non-reducing or reducing SDS-PAGE, probing for VP1. (C) 
RPTE cells on coverslips were infected with 10 thousand genomes/cell of purified mutant or wild-
type Dun virus and fixed at 24 hpi followed by staining for VP2/3 (red). One set of cells was 
infected with wild-type Dun and treated with BFA for 2 hpi immediately following adsorption of 
the virus.  
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of VP1 that enters the gel because all of the virus is still fully assembled. The VP1 disassembly 
intermediates were seen for both the wild type and mutant virus at 24 hpi (Figure 3.2B), 
suggesting that the mutant is able to disassemble in the ER similar to wild type virus. As another 
way to test trafficking of the mutant virus through the ER, the exposure of the minor capsid 
proteins was assessed. As the virus particle becomes partially disassembled in the ER, VP2 and 
VP3 become accessible to antibody recognition, and thus immunofluorescence detection of the 
minor capsid proteins is another readout for disassembly. For both mutant and wild type BKPyV, 
staining against VP2/3 showed similar levels of puncta throughout the cells, in contrast to cells 
treated with the trafficking inhibitor, Brefeldin A (BFA) (Figure 3.2C). Together these data show 
that disassembly and ER trafficking is still occurring during entry of the NLS-mutant virus. 
Therefore, the defect is likely occurring at a step between disassembly and nuclear entry. 
 
NLS mutation of the minor capsid proteins does not inhibit assembly of pseudovirions 
     Our next interests were in determining the role of the NLS of the individual minor capsid 
proteins during infection. Because the minor capsid proteins are encoded in the same reading 
frame, any mutation in the C-terminal sequence of one minor capsid protein will be shared by the 
other. To be able to manipulate the sequences of the minor capsid proteins individually, we 
turned to a pseudovirus system previously developed for the study of BKPyV(14). Pseudovirus 
particles are produced by over-expression of individual capsid proteins in 293TT cells, where 
they form capsid structures similar to wild type viruses, and can encapsidate a co-transfected 
reporter plasmid. It has been reported that pseudovirions of JC Polyomavirus, a closely related 
virus, behave identically to authentic virus during cellular entry and trafficking (15). Because the 





Figure 3.3: Wild-type and pseudovirion variants with NLS mutations form similar, non-empty 
particles. (A) After pseudovirions were purified by optiprep gradient, a picogreen assay was 
performed on each fraction from the gradient to measure double-stranded DNA. (B) Equal 
genomes of purified pseudovirion variants were resolved by reducing SDS-PAGE and probed 




manipulated. We transfected combinations of wild-type and NLS-mutant capsid expression 
vectors into 293TT cells along with a GFP reporter plasmid, and then we harvested and purified 
the pseudovirus particles by optiprep gradient. Wild-type, VP2 NLS-mutant, VP3 NLS-mutant, 
and double VP2/VP3-NLS mutant variants were created. During purification, each pseudovirus 
showed a band at approximately the same density in the optiprep gradient (data not shown), and 
the fractions from each gradient showed a peak of DNA at similar densities (Figure 3.3A), 
implying the reporter plasmid was encapsidated into pseudovirus particles. Additionally, the 
purified pseudovirion variants showed similar levels of each capsid protein by SDS-PAGE when 
equal genomes were loaded on the gel (Figure 3.3B). These data show that the defects in nuclear 
localization of the minor capsid proteins do not affect pseudovirus particle production.  
 
The VP3 NLS but not the VP2 NLS is important in 293TT cells 
     To evaluate the role of the individual minor capsid protein NLS during entry, we infected 
293TT cells with each of the pseudoviruses at equal GFP genomes per cell, then harvested 
protein at 48 hpi to measure GFP production. Because the reporter plasmid has an SV40 origin 
and the 293TT cells overexpress SV40 TAg, low levels of the GFP reporter are amplified, 
making the signal easier to detect. Interestingly, GFP levels as measured by western blot showed 
that pseudovirus with the VP2K319T mutation were as infectious as wild type, whereas the 
variants with the VP3K200T mutation and the double VP2/3KtoT mutations were attenuated by 
about 70% (Figure 3.4A). These data suggest that the NLS on VP3 is important for entry, while 
the NLS on VP2 is dispensable.  
     Next we were interested in validating this finding in RPTE cells. We infected RPTE cells 
with equal genomes of pseudovirus and harvested lysates at 48hpi, followed by assessment of  
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Figure 3.4: Pseudovirion variants with a VP3 NLS-mutation are defective for entry in 293TT 
cells. (A)293TT cells were infected with 1000 genomes/cell of pseudovirion variants and 
harvested at 48 hpi. Whole cell lysates were resolved and probed for GFP. A representative 
western blot is shown, and average GFP levels averaged from three independent infections and 
measured using the Odyssey system are graphed below it. (B) RPTE cells were infected with 10 
thousand genomes/cell of pseudovirions and whole cell lysates were harvested at 48 hpi. GFP 
levels from western blotting were measured using Odyssey, averaged from three independent 




GFP expression by western blot. Interestingly, GFP levels, while near the limit of detection, were 
similar for all four pseudoviruses (Figure 3.4B). This result is in contrast with the data from 
293TT infection and the mutant virus, suggesting there might be cell type differences in 
trafficking and nuclear entry during pseudovirion infection.  
 
Discussion  
     Polyomaviruses are abundant human pathogens whose infection can range from persistent and 
asymptomatic in healthy individuals to manifesting into devastating disease in 
immunocompromised patients, and at least one recently discovered polyomavirus is oncogenic 
(16). The cellular entry pathway of polyomaviruses is only partially understood, and many 
details remain to be elucidated. Previous studies have provided evidence that the virus is 
internalized and travels through endocytosis to the ER, where disassembly begins. After ER 
trafficking, the virus must get into the nucleus, and we and others have provided a model in 
which polyomaviruses exit the ER into the cytosol before nuclear entry, using the host pathway 
of ER-associated degradation. However, the mechanism of polyomavirus nuclear entry, and 
specifically BKPyV nuclear entry, has so far remained ill-defined. In this report, we have 
provided evidence that the nuclear localization signal on the minor capsid proteins of BKPyV is 
important during entry, suggesting that after the virus particle exits the ER, the minor capsid 
proteins play a vital role in the process of nuclear import.  
     Extensive work has previously been done on the nuclear localization properties of SV40 viral 
proteins, since the canonical NLS was first discovered on SV40 large TAg. Each of the capsid 
proteins separately were shown to localize to the nucleus and the necessary amino acid 
sequences were identified to include a QPNKKRR sequence (8). BKPyV has extensive 
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homology with SV40 and a number of conserved motifs, but the localization properties of 
BKPyV VP2 and VP3 have never been assessed, particularly in the context of infection and in a 
natural host cell, such as RPTE cells. We have demonstrated the nucleophilic property of both 
BKPyV VP2 and VP3 during overexpression in RPTE cells, and subsequently identified a lysine 
in the basic C-terminal sequence that was vital for this localization. Of note, expression of VP2 
or VP3 alone was low in RPTE cells, but this is likely due to their lytic properties. This idea is 
supported by the observation that more VP2/3 positive cells were detected at 24 h after 
transfection than at 48 h.  
     The identification of a lysine required for nuclear localization allowed us to create a mutation 
in the genome, changing the amino acid in both VP2 and VP3, to test the importance of the NLS 
of the minor capsid proteins during entry. Because the presence of wild-type VP1 allows for 
nuclear import of nuclear localization-deficient VP2 or VP3, we could not assess the localization 
defect during expression from the viral genome, since VP1 is expressed concurrently with VP2 
and VP3. However, we concluded that there was an obvious defect during entry, as determined 
by decreased levels of TAg expression from the mutant at 24 h, which is prior to the onset of 
viral DNA replication and capsid protein expression (unpublished data). Therefore, cause of 
lowered TAg levels would most likely be at the step of nuclear entry of the genome. We know 
the defect is not at an earlier trafficking step because VP2/3 exposure in the ER still occurs, and 
the capsid becomes reduced in the same way as wild-type. 
     The effect of the analogous mutation in the double-mutant pseudovirions in 293TT cells 
supports a role for the minor capsid protein NLS during entry as well, since pseudovirions only 
undergo single-round infection. Interestingly, results from the 293TT cells infection support a 
role specifically for the VP3 NLS during entry, since the mutation in VP2 alone had no 
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significant effect on GFP expression. However, the result of infection in RPTE cells with the 
pseudovirion variants complicates this conclusion, since there were no obvious differences in 
GFP expression levels between wild-type and mutant. An explanation for this may lie in 
potential differences between virus particles and pseudovirus particles; even though they are 
morphologically similar (17), since pseudovirion particles are formed under different conditions 
than in a normal infection, there could be variations in inter- and intra-pentameric disulfide 
bonds and/or Ca
2+
 ion stabilization. These differences could lead to different disassembly steps 
and subsequent trafficking into the nucleus in RPTE but not 293TT cells. Many differences exist 
between the two cells types, since 293TTs are immortalized and RPTEs are differentiated 
primary cells, and it is likely that nuclear import factors vary as well (18, 19). Additionally, 
293TT cells over-express SV40 TAg, leading to replication of the GFP reporter plasmid and 
amplification of any differences; thus, slight differences in nuclear entry in RPTE cells may just 
be below significance in this case. 
     A possibility that we cannot rule out is that the basic lysine residue in the NLS is needed for 
early gene transcription after the genome reaches the nucleus. It is unclear whether any or all of 
the capsid proteins accompany the viral minichromosome into the nucleus, although it has been 
shown for SV40 that the minichromosome alone is insufficient for nuclear import (20). Also, 
micro-injection of anti-VP3 antibodies into the cytoplasm or the nucleus of infected cells 
prevented infection with SV40 (20), suggesting that one or both minor capsid proteins play a role 
in nuclear import and/or post-nuclear entry steps.  
     The data in this report also suggest the possibility of an alternative nuclear entry pathway, 
since the NLS mutation only led to attenuated infection. One alternative way for cytosolic 
viruses to get into the nucleus is during mitosis, when nuclear envelope breakdown occurs. This 
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pathway could be evaluated by testing entry during inhibition of cell division. Additionally, it is 
possible that the virus still has use of an NLS. It is known that VP1 contains an NLS in addition 
to VP2 and VP3 (21, 22), but this motif is thought to be buried within the particle such that entry 
would rely on the other capsid proteins. However, it is possible that this NLS is available on 
BKPyV particles during entry in RPTE cells, or that another NLS exists in the context of the 
virus structure that does not exist when VP2 and VP3 are expressed individually. 
     In summary, this report shows the relevance during infection of a specific basic lysine in the 
C-terminus of the minor capsid proteins that is vital for nuclear import of the individual minor 
capsid proteins. Additionally, we show here the first evidence of a requirement for the VP3 NLS 
specifically, suggesting the VP2 NLS is redundant and VP2 serves additional functions during 
trafficking, upstream of nuclear import. Our data suggest a model where partially disassembled 
BKPyV exits the ER into the cytosol, where the exposed NLS of VP3 is used to bring the viral 
genome into the nucleus through the nuclear pore complex.  
 
Materials and Methods 
Cell Culture. RPTE cells were grown in renal epithelial basal growth medium (REGM) with 
SingleQuots Bulletkit from Lonza at 37°C and 5% CO2 and passaged up to six times as 
previously described (23). The 293TT cell line was maintained and not passaged more than 25 
times in DMEM with 10% heat-inactivated fetal bovine serum (HyClone), 100 U/ml penicillin, 





Transfection. The VP2 and VP3 expression plasmids were obtained from Addgene, Cambridge, 
MA (plasmid #s 32109, 32110). The VP1 expression plasmid was obtained from Christopher 
Buck, NCI, Bethesda, MD. RPTE cells in a 12-well were transfected using 3µl Mirus LT-1 
tansfection reagent, and 1 µg plasmid DNA following manufacturer’s instructions. LT-1 was 
mixed with 100µl Opti-mem and incubated 15 min before adding the DNA and incubating 25 
min at room temperature. To create pseudovirions, a T75 flask of <50% confluent 293TT cells 
were transfected with 13µg VP1 plasmid, 13µg of GFP reporter plasmid, 6.5µg of VP2 plasmid, 
and 6.5µg of VP3 plasmid using 85µl lipofectamine 2000. DNA and transfection reagent were 
incubated in 2ml Opti-mem separately for 25 min, then combined and incubated 45 min at room 
temperature before adding to the cells.  
 
Pseudovirion production. 293TT cells were harvested 3 days post transfection and 
pseudovirions were purified using a slightly modified version of the previously published 
method. Briefly, transfected cells were trypsinized, pelleted, and resuspended in DPBS-Mg in a 
siliconized tube. The cell pellet was treated with 1 U/ml of neuraminidase for 15 min at 37°C, 
followed by treatment with 1/20
th
 volume triton X-100 for 15 min at 37°C to lyse the cells. Then 
1/40
th
 volume 1M ammonium sulfate pH 9 was added along with 0.1% Benzonase and 0.1% 
Plasmid Safe and incubated about 24 h at 37°C for maturation. Following maturation, lysate was 
chilled on ice 5 min, 0.17 volumes of 5M NaCl were added, and lysate was incubated 20 min on 
ice. The lysate was clarified by centrifugation and extraction step repeated with 2 volumes 0.8M 
NaCl-DPBS, combined with first clarified lysate and re-clarified. The lysate was then layered on 
an optiprep gradient of 27%, 33%, 39%, and spun for 4.75 h at 49,000 rpm. Approximately ten 
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fractions were collected from each gradient. Picogreen assay was performed using 
manufacturer’s instructions and 20 µl of each optiprep fraction. 
 
Infections. Purified virus BKPyV (Dunlop variant) was propagated and purified as previously 
described (23). Crude TU, Dunlop, and mutants consisted of RPTE lysates that were infected for 
two weeks with a blind passage of RPTE cells that had been transfected with re-circulared viral 
genomes and harvested after 10 days. Before titering, crude stocks were freeze-thawed three 
times. Infections were done in REGM or serum-free DMEM at 4°C for one hour, and then the 
inoculum was washed off and replaced with warm media with serum and placed at 37°C for the 
indicated time frame.  
 
Quantitative PCR (qPCR) titering of genomes. To calculate genomes per volume, 5 µl of 
virus or pseudovirus was treated with 2 µl DNAse for 1 h at 37 C, then treated with 50µg 
proteinase K for 1 h at 37, followed by isolation of the viral genomes by a PCR purification 
column. Dilutions of the isolated DNA were used for qPCR and final concentrations were back-
calculated to get genomes per ml. For BKPyV, qPCR was done using primers 5’ 
TGTGATTGGGATTCAGTGCT 3’ and 5’ AAGGAAAGGCTGGATTCTGA 3’in the TAg 
open reading frame. For pseudovirions, primers 5’AGAACGGCATCAAGGTGAAC 3’ and 
5’TGCTCAGGTAGTGGTTGTCG 3’ against the GFP open reading frame were used.  
 
Preparation of cell lysates. Whole cell protein lysates were harvested in E1A buffer (50mM 
HEPES pH 7, 250 mM NaCl, 0.1% NP40, with protease inhibitors 5 µg/ml PMSF, 5 µg/ml 
aprotinin, 50 mM NaF, 0.2 mM Na-orthovanadate, and 5 µg/ml leupeptin added right before 
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use). For alkylating conditions, 20mM N-Ethyl Maleimide (NEM) was added to the E1A buffer. 
Protein concentrations were determined using a Bradford assay after clarifying the lysate. 
 
Western Blots. Equal amounts of protein were resolved by SDS-PAGE on a 10% gel (8% for 
TAg), under reducing or non-reducing conditions and transferred overnight onto a nitrocellulose 
membrane at 60 V by wet transfer. Membranes were blocked in 2% nonfat dry milk in PBS 
containing 0.1% Tween 20 (PBS-T).  Antibodies were used at the following concentrations 
diluted in PBS-T: anti-TAg 1:3000, anti-VP1 1:10,000, anti-VP2/3 1:3000, anti-GFP 1:2000, 
anti-B-Actin 1:5000, anti-mouse 1:5000, anti-rabbit 1:5000. For western blots analyzed by the 
Odyssey system, membranes were blocked in Odyssey blocking buffer and probed with the 
indicated primary antibodies or anti-mouse or anti-rabbit secondary antibodies diluted in 
Odyssey blocking buffer with 0.1% Tween 20.  
 
Immunofluorescence microscopy. At 24 hours post transfection, cells were fixed with cold 
95% EtOH/ 5% acetic acid. Cells were blocked with 5% goat serum in PBS, then coverslips were 
co-stained for indirect immunofluorescence with 1:500 dilution of anti-VP2/3 in goat serum. 
Secondary antibodies Alexa-Flour
®
 594 goat anti-rabbit IgG or Alexa Fluor
®
 488 goat anti-
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Summary and Model of BKPyV trafficking  
     The findings presented in this dissertation answer many questions about how BKPyV reaches 
the nucleus and provide a more solid model for the BKPyV intracellular trafficking pathway in 
RPTE cells (Figure 4.1). I have provided evidence for a trafficking pathway where BKPyV 
travels to the ER and uses the ERAD system to get out of the ER and into the cytosol. From 
there, the virus is imported into the nucleus by way of the NLS on the minor capsid proteins. I 
also have evidence that multiple other trafficking pathways may exist, including non-productive 
pathways and alternative nuclear entry pathways. These experiments were carried out in RPTE 
cells, a cell culture system that involves primary kidney cells, a cell type known to be infected 
with BKPyV in diseased patients, making these results translatable to lytic infection in vivo (1).  
 
Polyomavirus ER membrane penetration 
     In Chapter 2, we investigated the role of ERAD machinery and the proteasome during the 
course of BKPyV infection in RPTE cells. Before these studies began, there was much evidence 
for involvement of ER proteins as factors in the uncoating of polyomaviruses. As reviewed in 
chapter one, some of these factors were chaperones known to also play a role in ER quality 




Figure 4.1. Model for BKPyV trafficking from the ER to the nucleus. First, (1) BKPyV 
traffics to the ER where (2) partial disassembly occurs, including reduction of disulfide 
bonds within and between VP1 pentamers, and conformational changes that expose VP/3 
for antibody staining. After partial disassembly, (3) the particle interacts with yet-
unknown ERAD components that allow it to cross the ER membrane into the cytosol. A 
proteasome-independent retrotranslocation mechanism also allows for VP1 protein to 
enter the cytosol that does not come from productive virus particles. Once in the cytosol, 
(4) the NLS on the minor capsid protein is used for nuclear import of the virus through the 
NPC, though it does not seem to be the only nuclear import mechanism.  
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for the ER-associated degradation pathway during polyomavirus infection was initially implied 
from studies of the derlin proteins and the proteasome during the course of infection (2-4).  
     Our investigations of proteasome function during BKPyV infection revealed that the virus 
relied on the ER quality control pathway of which the proteasome is a part. Inhibiting the 
proteasome caused an accumulation of virus within a specialized compartment within the ER 
called the ER quality control compartment (ERQC), normally characterized by ERAD substrates. 
The data suggest that the virus becomes sequestered to this compartment under conditions where 
the ERAD pathway is blocked. Since it must be recognized like an ERAD substrate, there is 
likely a hydrophobic patch or perhaps a protein-binding motif recognized by ERAD chaperones. 
Geiger et al. found that glutamic acid 17 in the N-terminal sequence of SV40 VP2 was essential 
for transport of the virus into the cytosol (5), and suggested that this negatively charged reside 
may be recognized by ERAD factors. It was also shown that SV40 requires the ER proteins BiP 
and Bap31 in order to get out of the ER, and these proteins colocalize with the virus in distinct 
puncta during infection (5). Bap31 has also been implicated in the transport of quality control 
substrates to the ERQC, so perhaps Bap31 is the factor that sequesters the virus in the 
subcompartment after proteasome function is inhibited (6). Since BiP has been shown to be 
required for retrotranslocation of polyomaviruses, the re-localization of the virus to the ERQC 
during proteasome inhibition may provide an explanation for why infection is inhibited. BiP is 
excluded from the ERQC, and without the required factors, polyomavirus retrotranslocation is 
blocked.   
     How the virus actually crosses the ER membrane, especially as a large intact particle, remains 
a mystery. The prevailing theory states that the membrane lytic properties of the minor capsid 
proteins allow for penetration of the lipid bilayer, and this may be assisted by the ER associated 
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degradation machinery and putative retrotranslocation pore to allow for the virus to pass through 
into the cytosol. It has been shown that both VP2 and VP3 can interact with membranes (7, 8), 
but since the ER membrane is not damaged during infection, it is likely that membrane insertion 
may be one regulated step in the translocation process. There are multiple forms of ERAD 
depending on whether the substrate is soluble (ERAD-L) or membrane integrated, and whether 
the structural irregularity is located on the lumenal (ERAD-M) or cytosolic side (ERAD-C) of 
the ER membrane (9). These different ERAD pathways utilize different sets of factors. It seems 
likely that integration of VP2 into the ER membrane might lead to recognition of the virion as a 
membrane-integrated substrate. The membrane-integrated viral particle may then rely on the 
assistance of ERAD-M. Unfortunately, this pathway is less understood than ERAD-L, and thus 
further progress in this field of cell biology would benefit the field of polyomavirus trafficking.  
     The particle that exits the ER would be larger than any normal ERAD substrate, since capsid 
proteins are likely to be transported along with the genome. Since the viral substrate is larger 
than usual, the mechanism of crossing the membrane would likely be different than that of a 
normal substrate. Perhaps the viral proteins facilitate the assembly of a pore-like opening that 
consists of both cellular and capsid protein components to make it custom size. Evidence 
presents a scenario where many more virus particles accumulate inside the ER lumen than 
eventually make to the cytosol or nucleus, so it is possible that the capsid proteins from some 
virus particles act as part of the pore, while a different one makes it across the membrane. 
Additionally, evidence shows that SV40 VP3 has the capacity to oligomerize compared to VP2 
(8), so while VP2 serves the function of membrane integration, VP3 may allow penetration into 
the cytosol.  
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     Another interesting question is where the energy comes from to pull the virion across the ER 
membrane. For normal ERAD substrates, it is believed that the process of ubiquitination and 
deubiquitination and the ATPase activity of p97 pull the substrate out of the membrane towards 
the proteasome (9, 10). Ubiquitination of viral capsid proteins has yet to be detected, however, 
and we found that inhibition of p97 by the small molecule inhibitor Eeyarestatin I did not prevent 
viral DNA from entering the cytosol. These findings suggest that the virus must rely on another 
mechanism for favorable movement of the particle into the cytosol, yet to be described.  
     An important issue that exists is the discrepancy between the appearance of VP1 monomers 
and viral DNA in the cytosol of different cell types. One explanation may be that disassembled 
VP1 monomers that dissociate from the virion during uncoating in the ER end up undergoing 
ERAD. With inhibition of the proteasome, perhaps in RPTE cells the VP1 monomers, likely 
soluble ERAD substrates, can still undergo the retrotranslocation process but are not degraded, 
resulting in cytosolic accumulation of the monomers. This would not be difficult to reconcile 
with the inhibition of retrotranslocation of the larger particle, since different machineries seem to 
be used. It is interesting that this does not occur for SV40 in CV-1 cells, but perhaps the ERAD 
machinery and requirements are different in that cell type. It is obvious that cell type differences 
exist, and one of these differences may be at the step of membrane penetration. A study with 
MCPyV showed that VP2 is not important for infection with certain cell types, while in some 
cell types it increases the infectivity of the virus (11). MCPyV proteins exhibit much less 
homology to BKPyV and SV40, and it has been shown for MCPyV that VP3 is unnecessary for 
infection, even though it is still encoded in the genome. It was hypothesized that the MCPyV 
VP1 had perhaps evolved to take over some functions of the C-terminal motifs of VP2 and VP3, 
making VP3 unnecessary. The VP2 of MCPyV still contains homology to BKPyV and SV40 in 
99 
 
the N-terminus, with the myristoylation still present, so perhaps the function of membrane 
integration is a cell-specific necessity, while the functions provided by VP3 are required for all 
cell types. This was supported in the report by showing that BKPyV VP2 and VP3 were 
important for all cell types, since VP1 of BKPyV has not gained the VP3-specific function (11).   
      While the favored model involves a mechanism where the virus particle crosses the ER 
membrane and enters the cytosol, another scenario may also exist where the productive virus 
particle penetrates the ER membrane to become a membrane-integrated complex, but does not 
actually enter the cytosol. Cytosolic viral components may then be only non-productive side 
products of a transiently permeabilized ER membrane. There is currently no evidence that the 
ER membrane becomes simply “leaky” based on western blots of ER proteins in the cytosolic 
fractions of infected cells, but it may be at an undetectable level. The membrane-associated 
particle would still rely on the nuclear pore complex in order to make it inside the nucleus, but 
transport would occur in the plane of the ER membrane, interacting with transmembrane factors 
that are used for trafficking of inner nuclear membrane proteins. We tested whether one of the 
factors, sec61β, implicated in ER membrane - to - inner nuclear membrane transport of 
epidermal growth factor receptor, was involved during BKPyV infection using siRNA 
knockdown (12). However, there was no negative effect on TAg expression when sec61β protein 
levels were decreased (Figure 4.2). This result may rule out the sec61β-mediated route during 
infection, or it may be that low levels of sec61β protein provide enough function to allow 
infection.   
     Penetration of the limiting membrane is a shared obstacle for all nonenveloped viruses.  
Adenovirus must escape the endosome into the cytosol, and the current model for this is the 




Figure 4.2. Sec61B knockdown does not block BKPyV infection.  RPTE cells were 
tranfected with non-targeting (NT) or sec61β siRNA or mock transfected for 2 days, 
then infected with BKPyV at MOI 1 for 24 h. Whole cell lysates were harvested and 
resolved by SDS-PAGE and probed for TAg, Sec61 β, and β-actin. Results are 
representative of three independent experiments.  
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endosome (13). This large disruption is necessary because the partially disassembled adenovirus 
particle is relatively large at 90 nm. Since endosomes are smaller transient organelles, using this 
system to cross the membrane would not harm the cell. Disrupting the ER membrane would be 
quite harmful for a cell and would not be beneficial for a virus like BKPyV that takes at least 48 
hours to produce progeny. Other potential mechanisms of membrane disruption include the 
formation of pores or transient local disruption of the lipid bilayer. Parvovirus is believed to 
cause a transient membrane disruption using the phospholipase 2 domain in its capsid protein, 
allowing penetration of the virus without leakage of any other substances from the compartment 
(13). However, the mechanism has not been fully described. Understanding the mechanics of 
viral protein membrane penetration is an area where there is much still to be understood.  
 
Nuclear entry mechanism  
     In Chapter 3, I showed that mutation of a residue in the minor capsid proteins important for 
nuclear localization led to an attenuation of virus infectivity, implying a role during entry. This 
finding complements a model where BKPyV traffics through the cytosol, interacts with the 
canonical nuclear import machinery using the NLS on the minor capsid proteins, and is imported 
through the nuclear pore complex. If this pathway was vital during infection, it would suggest 
that the direct ER–to–nucleus alternative trafficking route could be ruled out, unless both 
pathways exist in order to provide the most opportunity for the virus to reach the nucleus. 
However, neither pathway can be ruled out at this time, since the mutations that we created 
caused only an attenuated phenotype and did not prevent infection. One possible explanation for 
this is that the NLS can still be used but to a lesser degree. Since the virus particle would likely 
still consist of multiple copies of the minor capsid proteins, together they may act to increase the 
102 
 
nucleophilic potential of the entire particle. Another explanation may be that there is another 
NLS that exists. This possibility was ruled out when the cytoplasmic localization of the mutants 
was verified by transfection, but another NLS may exist in the structural context of the particle. 
VP1 has an NLS, but it is believed it is not available during entry based on conclusions from 
studies of SV40 (14). Perhaps in BKPyV, this NLS is more available to interaction with 
importins. A third explanation may be that another pathway to the nucleus exists that is 
independent of the use of an NLS. Dividing cells experience nuclear envelope breakdown, such 
that any cytosolic virus could access the nucleus during the process of mitosis. Additionally, a 
route directly across the inner nuclear membrane has not been ruled out, and this would be an 
NLS-independent mechanism.  
     The use of an NLS implies that importin β is involved, and interestingly, importin β has been 
implicated during retrotranslocation of ERAD substrates as it was found to interact with the 
ERAD machinery (15). This finding may suggest that the trafficking of BKPyV from the ER to 
nucleus is coupled in a way to provide some kind of favorable movement out of the ER into the 
nucleus. If we consider the possibility that VP3 plays a separate role from VP2 membrane 
integration, then the attenuation of the VP3 NLS-mutant pseudovirion variant in 293TTs might 
be explained. Perhaps the VP3 NLS is required for interaction with the nuclear import machinery 
because VP2 is performing an upstream function within the ER. The function of the VP3 NLS 
could be simply for nuclear import, or perhaps it interacts with importin β in the context of 
ERAD to pull the virus out of the ER. It is unclear, however, why the pseudovirion variants did 
not exhibit these differences in RPTE cells. 
     Other viruses that must access the nucleus have shown us that use of the NPC or other aspects 
of the canonical import pathway do not imply that all aspects of the pathway are used. Hepatitis 
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B virus (HBV) was found to use the canonical nuclear import pathway, including importin β 
mediated nuclear transport, but not RanGTP. HBV capsid protein interacts with Nup153, which 
displaces the interaction with importin β in the same way as normally occurs with RanGTP 
interaction with importin β (16). Adenovirus uses the nuclear pore complex, but not importins; 
nuclear entry was found to be combined with final steps of genome uncoating, such that 
disassembly of the capsid is combined with removal of certain NPC components. Ultimately, 
nuclear envelope permeability is increased, allowing access of the adenovirus genome into the 
nucleus (17).  
     We attempted to test the importance of the canonical nuclear import pathway during entry by 
treating infected cells with the small molecule inhibitor Importazole, which was identified in a 
screen and prevents the interaction of importin β and RanGTP (18). Interestingly, treatment with 
the inhibitor prevented infection, but at an early step in entry preceding ER trafficking. 
Additionally, we found that adding Importazole any time after 6 hpi was no longer inhibitory, 
implying that the early step was the only step in which the drug was preventing the infectious 
route. Since there have been relatively few studies with this new small molecule inhibitor, this 
finding suggests that there may be off-target effects besides the RanGTP-importin β interaction. 
Alternatively, a very early signaling event necessary for infection and reliant on RanGTP-
importin β is perhaps being inhibited. If RanGTP is not required during infection, this may 
provide evidence against the canonical nuclear import pathway, or it could be that a BKPyV-
specific nuclear import pathway exists like that of adenovirus or HBV.  
  
Alternative and non-productive trafficking routes  
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     From the presence of VP1 cleavage products over time, cytosolic VP1 monomers appearing 
in a disproportionate levels with cytosolic DNA, and a high particle to infectivity ratio, it is 
obvious that there are a considerable number of non-productive paths during BKPyV infection of 
RPTE cells. It seems that there is a limiting step during the trafficking of the virus towards the 
nucleus, since we detect such low levels of viral DNA in the cytosol. Some virus seems to 
accumulate as a result in the ER, and we have evidence of this since we can see VP2/3 puncta 
staining throughout the cell even after DNA replication has started at 48 hpi. It is unclear what 
occurs with this lingering virus once the minimum infectious viral genomes reach the nucleus. 
Can late-arriving viral genomes continue on to nuclear entry to follow the normal infection cycle 
if the infection-specific changes have begun in the nucleus? If the ERAD pathway already 
recognizes viral proteins, the viral particles may just continue to undergo retrotranslocation into 
the cytosol. Once in the cytosol, viral proteins may be degraded by the proteasome or continue 
on to the nucleus. Additionally, cytosolic viral aggregates may be cleared by autophagy. 
     The other mechanism of degradation and cleanup used by the cell is lysosomal degradation. It 
seems very likely that a portion of incoming virions may end up degraded by the lysosome, since 
the endocytic pathway used by polyomaviruses is thought to continue to the late endosomes and 
endolysosomes (19). If the endocytosed virions do not reach the ER, then they likely go on to be 
degraded in the lysosome. This conclusion is supported by our trafficking studies of BKPyV 
using the less-specific proteasome inhibitor MG132, which is known to also inhibit certain 
cysteine proteases located in the lysosome. Treatment with MG132, compared to other specific 
proteasome inhibitors epoxomicin or lactacystin, causes a larger amount of VP1 monomers to 
appear in both the cytosolic and pellet fractions after cytosolic fractionation. This may be due to 
escape of virions from lysosomal degradation. There is no corresponding increase in infection, 
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however, likely due to the additional inhibition of proteasome activity. Previous efforts by the 
lab to identify the source of the VP1 cleavage products initially implicated cathepsins, but no 
increase or decrease in infection occurred under cathepsin inhibitor treatment.  
 
Future directions 
     One of the biggest issues in the field has been to determine the infectious route to the nucleus, 
and it has yet to be determined whether the apparent cytosolic pathway is the one and only route. 
It has been attempted to address trafficking questions through EM studies of infected cells, 
looking for visual clues as to the route of virus entry. One ultrastructural study of a nephropathy 
biopsy showed that there are many virus particles in the ER and virus aggregates in the 
cytoplasm, and there are disturbances in the nuclear membrane, but no sign of viruses entering 
directly through the nuclear envelope or through the nuclear pore (20). These observations from 
EM studies have yet to be reconciled with results from biochemistry and cell biology studies. 
Theoretically it should be possible to gain insight from direct visualization of infecting viruses, 
but with the high amount of nonproductive pathways followed by BKPyV virions, it creates the 
task of finding a needle in a haystack. Biochemical methods have the problem of teasing apart 
results from productive versus nonproductive pathways. In the future, EM studies could benefit 
from correlative fluorescence and electron microscopy, merging what we know about the cell 
biology of infection with visualization of the virus particles on a cellular level to minimize the 
proverbial haystack. For example, we can stain for VP2/3 and BiP or Bap31, since they are 
believed to represent areas of retrotranslocation based on what was shown with SV40 (5). After 
finding areas of colocalization, we can zoom in using EM to see if one or multiple viral particles 
are creating a disturbance in the membrane. Additionally, we can compare what the viral 
106 
 
particles look like in proteasome-treated cells compared to untreated, to see if there is a 
difference in their pattern or structure. For treated cells, we would have to focus on virus that 
was not colocalized with BiP, to see how those particles that are not part of active 
retrotranslocation complexes interact differently with the cell. More colocalization studies may 
need to be done first on proteasome inhibitor-treated cells before subsequent correlative EM is 
used for comparison with untreated. Besides the ER membrane penetration step, other aspects of 
trafficking can be addressed using correlative microscopy such as nuclear entry. Co-staining can 
be done for VP2/3 or viral genomes along with nuclear pores or envelope markers, and any 
proximal or co-localizing areas can then be imaged by EM to attempt to capture the process of 
nuclear entry.  
     The mechanistic details of how BKPyV crosses the ER membrane are very intriguing and 
would be an area of high technical difficulty but great reward for the field of nonenveloped 
viruses. So far, our understanding is limited partly because the mechanism of ERAD is also not 
clearly understood. As has been done to elucidate the important factors in retrotranslocation of 
model ERAD substrates, the development of an in vitro membrane penetration assay for 
polyomaviruses would be ideal (21). Necessary cytosolic components could be identified by 
isolating microsomes from infected cells, and then incubating with full cytosolic extract or 
extract with components depleted, such as importins, other chaperones, etc. In order to evaluate 
the necessity for different ER lumenal or transmembrane components, the microsomes would 
have to be isolated from infected knockdown or knockout cells. This would be technically 
difficult but extremely informative.  
     A number of details can be attained through development of more in vitro assays. It would be 
valuable to develop a nuclear import assay in order to gain a better understanding of the nuclear 
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entry mechanism of BKPyV. This can be done using a previously developed nuclear import 
assay where cells are grown on coverslips and permeabilized with digitonin, which will leave the 
nuclear envelope and pores intact (22). Then different BKPyV substrates can be tested for import 
into the nucleus, using the visualization of VP2/3 or viral genomes by fluorescence as a readout 
for nuclear entry. Many questions can be asked using this assay, starting with the structure of the 
particle that undergoes import. Purified virus would be treated with ER lumenal extract to mimic 
the uncoating process within the ER. These disassembled particles would then be used to show 
whether or not nuclear import can occur, and whether it occurs through the nuclear pore complex 
by treating with the nuclear pore complex inhibitor wheat germ agglutinin. Additionally, the 
cytosolic cellular factors that are required for nuclear import can be evaluated by selective 
removal from the transport buffer in which the assay takes place. This can be done to evaluate 
the need for importin α or β, or any other cytosolic factors that may play a role in nuclear entry. 
     Another interesting avenue that can be explored is the difference in trafficking between 
different cell types. This could be informative in the context of in vivo infection. We found a 
number of differences between the trafficking of BKPyV and SV40 in RPTE cells versus CV-1 
cells, which differ in both species origin as well as transformed versus primary cell properties. It 
may be important to look at the trafficking of BKPyV in other primary cells that may be infected 
in the body, such as urothelial cells or other kidney cell types. This could be done using the same 
assays as used in this thesis so that results could be directly compared. Trafficking differences 
between cell types could mean differences in innate immune recognition or responses. 
Interestingly, our lab found that there was no obvious immune response from BKPyV infection 
at 24, 48, or 72 hpi in RPTE cells through microarray analysis (23). Perhaps BKPyV cleverly 
evades immune detection in that cell type but does not in others. It would be important to 
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determine since it has been suggested that the immune responses, although it was adaptive 
immunity that was implicated, are thought play an important role in pathogenesis in a mouse 
model of PVAN (24). The findings from this study were interesting because high virus titers did 
not correlate with disease state, suggesting that the virus itself is not enough to cause the damage 
seen in diseased tissue. Besides the differences in cell entry or immune responses, different cell 
types may be important to study for the sake of understanding persistence and reactivation of 
BKPyV in vivo.  
 
Significance for the Field 
     Before this work began, one of the major questions in the field was whether polyomaviruses 
indeed traveled through the cytosol and if this was a productive pathway. Previous studies with 
SV40 had suggested that the virus could traffic from the cytosol into the nucleus, since 
microinjection of virus into the cytoplasm was able to result in infection, and injection of 
antibodies into the nucleus prevented this infection (25). Since the injected virus would 
theoretically not have undergone the disulfide bond reduction and isomerization within the ER, it 
was curious how the viral genome would have come to be uncoated for transcription and 
replication. Development and advancement in biochemical approaches has provided more 
techniques for addressing intracellular trafficking questions and applying these questions to 
viruses. The digitonin-based retrotranslocation assay, first developed to show retrotranslocation 
of ERAD substrates (26), allowed a number of groups including us to show the presence of 
polyomavirus in the cytosol, a long sought-after question. There is no doubt that more questions 
will be cleared up about polyomavirus entry with more sophisticated research techniques. 
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      Besides the contributions this work has provided about polyomavirus trafficking in general, 
this is the first analysis of BKPyV trafficking through the cytosol in a natural host cell type. Most 
of the previous data from which we have made inferences came from studies of SV40 in 
transformed cell lines. For that reason, this study includes the most relevant data about 
polyomavirus cytosolic trafficking in a natural host cell, as well as the most current data about 
BKPyV-specific trafficking. Furthermore, the different results attained in RPTE cells as 
compared to CV-1 cells and 293TT cells have demonstrated that important differences exist in 
different cell types, and these differences represent not only important variables to consider for 
experiment design, but also that different cell types in the body may play different roles during 
viral persistence and reactivation in the host. 
     It could be said that many more questions were raised from the work in this dissertation than 
were answered. This work verified the cytosolic trafficking of BKPyV at the same time as other 
work was published showing the cytosolic trafficking of SV40, along with confirmation of the 
ERAD pathway’s involvement during entry and the potential role for the NLS of the minor 
capsid proteins. Additionally, the findings and discussions throughout these chapters raise 
important issues of cell type differences in the trafficking pathways and the always present 
question of whether it is a productive pathway that is being examined. These are vital points that 
are important for the field of polyomavirus trafficking and will allow future research to move 
forward more quickly towards a better understanding of polyomavirus infection. 
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